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Irregularities in cellular energy metabolism have been linked to many human diseases, 
including metabolic disorders, mitochondrial diseases, cancer, and neurodegeneration. In order 
to survive and function properly, an adequate supply of energy is necessary. When cells are 
exposed to energy stress or pathologic stimuli, they have the ability counteract decreased 
energy status by activating adaptive mechanisms, which can theoretically be referred as 
metabolic rewiring. More scientific knowledge about the molecular mechanisms involved in 
metabolic rewiring may facilitate development of new targeted therapeutic strategies. 
In this study, we investigated the effects of genetic manipulation and the mechanisms of 
metabolic adaptation in cultured cells, and how these correlates with changes in key metabolic 
and physiological functions under different conditions of energy stress. We particularly 
mimicked pyruvate dehydrogenase (PDH) dysregulation in MDA-MB-231 cell line by 
inducing overexpression of all four isoforms of pyruvate dehydrogenase kinase (PDK1-4).  
Successful overexpression of each of the PDK isoforms was confirmed by quantitative real-
time PCR and western blot analysis. We found that increased PDK1-4 expression is associated 
with increased proliferation in modified MDA-MB-231 cells, particularly in PDK1, PDK3, and 
PDK4 overexpressing cells. We carried out a series of cell proliferation assays in high (25 
mM), moderate (5 mM) and low (1 mM) glucose to investigate the effect of glucose supply on 
growth of PDK-overexpressing cells. We observed that PDK1-4 overexpression triggers a 
reduced cellular tolerance in glucose deprived condition and conversely, they exhibited an 
increased dependence on high glucose. Besides, Inhibition of PDK by Dichloroacetate (DCA) 
was found to cause a drastic reduction in proliferation in these cells. 
Subsequent metabolic adaptation was observed towards increased mitochondrial respiration 
and glycolysis in the PDK-overexpressing cells, mostly in the PDK1 expressing cell. However, 
pyruvate oxidation was reduced by PDK overexpression, as expected. One remarkable finding 
of this study is PDK-overexpression was found to trigger a metabolic switch towards increased 
fatty acid oxidation. In cells overexpressing PDK1 or PDK2, fatty acid oxidation was increased 
in low glucose condition, whereas in PDK3 or PDK4 overexpressing cells, fatty acid oxidation 
was increased in high glucose condition. 
Our findings suggest that PDK overexpression is associated with subsequent metabolic 
rewiring in cultured cells, characterized by increased dependency of glucose for growth, 
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changed utilization of energy substrates, and increased rates of both glycolysis and 





In order to survive, having a source of energy is essential. Mammalian cells possess special 
mechanisms to produce energy from the breakdown of food we eat. The energy is utilized by 
the cells in the form of a versatile energy molecule, adenosine triphosphate (ATP). Energy 
homeostasis must be balanced by supporting the adequate production of ATP so that living 
cells can grow, reproduce, maintain structures and respond to environmental changes [1]. If the 
cell is unable to meet appropriate metabolic requirements, the homeostasis might be threatened, 
which may induce cell death and pathological conditions including cancer, neurodegeneration, 
metabolic syndrome, cardiovascular disease and more [2, 3]. To prevent such effects, cells need 
metabolic flexibility to adapt to conditional changes in energy supply and demand. This might 
be achieved by switching between substrates or activating rescue mechanisms to avoid 
potential stresses [4]. A cell’s ability to be metabolically flexible is determined by the 
mitochondrial function, since mitochondria are the central organelles for metabolic processes 
[5]. This thesis focuses on characterizing adaptive mechanisms of cultured cell lines with 
regards to manipulation of mitochondrial function in varying conditions of energy stress. 
1.1 The Mitochondrion: origin, structure, genetics, and function 
Mitochondria derived their names from the Greek word ‘mitos’ meaning thread and ‘chondros’ 
meaning small granules, due to their thread-like structure when observed under a light 
microscope [1]. They occupy a substantial portion of the eukaryotic cell cytoplasm and are 
considered as metabolic headquarter of the cell. Mitochondria arose from the engulfment of an 
α-proteobacterium by a primitive eukaryotic cell over two million years ago. A relic of this 
event is that the mitochondrion maintained its double membrane character as its ancestors and 
is the only organelle that has its own DNA [6, 7]. All human cells contain mitochondria, except 
mature erythrocytes [8]. The size, shape and copy number of mitochondria in a cell depend on 
the type of  cell and the cell’s metabolic energy demand [9]. 
Mitochondria can be found as stiff, elongated cylinders or dynamic tubular network of 
interconnected mitochondria, with a diameter 0.5–1 μm. They have been found as remarkably 
mobile and plastic, and continuously changing their shape, as observed under light microscope 
[9, 10]. The structure consists of a mitochondrial matrix surrounded by the inner and outer 
mitochondrial membranes (IMM and OMM); between the two membranes, there is a narrow 
intermembrane space (IMS) (see Figure 1.1). The matrix contains most of the mitochondrial 
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proteins, including the enzymes involved in the tricarboxylic acid (TCA) cycle, fatty acid (FA) 
oxidation, iron-sulfur (Fe-S) biogenesis, and others [11] .The mitochondrial DNA (mtDNA) is 
also found in the matrix. In the IMM, the mitochondrial oxidative phosphorylation (OXPHOS) 
machinery consisting of  the electron transport chain (ETC) complexes (complxes I-IV) and 
the ATP synthase complex (complex V) is located, and also protein complexes involved in 
transporting ions, metabolites and proteins through the IMM. [12]. The IMS contains some 
proteins for cristae remodeling and apoptosis factors. The OMM contains porin proteins that 
allow influx and efflux of metabolites and proteins involved in mitochondrial fission and fusion 
[13, 14].  
 
 
Figure 1.1 Simplified illustration of human mitochondrion with its structural parts. The 
mitochondrion has two membranes: inner and outer membrane (IMM and OMM); between 
these two, there is an intermembrane space. The IMM is folded into cristae that encloses the 
mitochondrial matrix. The electron transport chain (ETC) is in the IMM and the matrix holds 
the mitochondrial DNA (mtDNA) and ribosomes. Adapted from [15] 
 
The mitochondrial genome contains multiple copies of small circular DNA that are maternally 
inherited and is distinct from the nuclear genome. The mtDNA contains coding information for 
13 protein subunits of the ETC complex, 22 for transfer RNAs and two for ribosomal RNAs; 
encoding 37 genes in total.  However, more than 98% of the protein complement needed for 
overall mitochondrial function are encoded by the nuclear genome [13, 16]. 
Mitochondria produce most of the cellular ATP and important contributors in different 
signaling pathways that are crucial for organism survival. They are also involved in cellular 
adaptation to environmental stimuli, production of reactive oxygen species (ROS), apoptosis 
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and in intracellular Ca2+ signaling [6]. The mitochondrial biomass and functional quality is 
maintained by a combination of process including metabolic adaptation, mitophagy, 
mitochondrial biogenesis and often accompanied by changes in morphology (e.g fission, 
fusion) [7]. 
1.2 Cell metabolism 
The word ‘metabolism’ comes from the Greek ‘metabolē’ which means ‘change’. It is the sum 
of chemical reactions occurring in the living organisms that allow organisms to maintain life 
[17]. The sum constitutes more than 8,700 reactions and 16,000 metabolites that have been 
annotated in the Kyoto Encyclopedia of Genes and Genomes (KEGG). The core metabolic 
reactions can be categorized as catabolic- the breakdown of substrates to produce energy and 
anabolic- using energy to build up components [18]. Thus, metabolism serves three purposes 
in an organism: 1. breaking down food into energy for vital processes, 2. conversion of food or 
fuel to building blocks of life such as protein, lipids and nucleic acids, and 3. the excretion of 
metabolic wastes (e.g. nitrogenous wastes). All the chemical reactions are organized into 
different metabolic pathways and carried out through a series of steps; each step facilitated by 
an enzyme. Enzymes function as catalysts to allow reactions to proceed rapidly and regulate 
the rate of metabolic reaction [3, 19]. 
1.2.1 Energy substrates and whole-body energy homeostasis  
The main energy substrates of body metabolism are carbohydrates, lipids and proteins that 
come from the foods we eat. After digestion, the simplified food molecules are distributed to 
all tissue through the circulation via blood vessels. A set of tightly regulated transport 
mechanisms are involved in the uptake of molecules by the cells from the bloodstream [20]. 
Inside the cells, metabolic processes that convert sugar, FAs, and amino acids into energy 
occurs in multiple sites through specialized metabolic pathways. For instance, in the cytosol, 
we find glycolysis whereas in mitochondria; TCA cycle, FA oxidation and OXPHOS system 
contribute to the production of ATP [2]. Figure 1.2 show an overview of substrate conversion 




Figure 1.2 An overview of interplay between different metabolic pathways. Intermediates 
or end products from glucose metabolism, lipid metabolism and amino acid metabolism can 
serve as energy substrates for TCA cycle that eventually produce fuel molecules for ATP 
production. Modified from [21] 
 
 
How the body will utilize different substrates depend on the type of the tissue, oxygen 
availability, metabolic state (fed or starved) and energy demand (resting or exercise). For 
example, red blood cells (RBC) only utilize glucose since they lack mitochondria. Similarly, 
the brain alone uses 130g of glucose per day since it cannot use FAs [22]. Alternatively, FAs 
are the preferred fuel for skeletal and heart muscle cells during resting states [23]. However, 
when the preferred substrates are unavailable, alternative substrates may be utilized instead; an 
example includes the use of FA derived ketone bodies by the brain when glucose is not 
available [24]. During fasting, FAs are taken up by the liver cells and are used to make ketone 
bodies and ATP to fuel  gluconeogenesis which helps to maintain glucose levels above 3.5 
mmol/L [3]. In diabetes, a similar shift occurs due to deficient glucose uptake which may lead 
to diabetic ketoacidosis if not controlled [25]. Some tissues switch between substrates 
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depending on the workload, such as in skeletal muscle, plasma free fatty acids (FFA) provide 
most of the energy during resting or low intensity exercise. When exercise intensity increases, 
plasma FFA turnover does not increase and the additional energy demand is met by using 
muscle glycogen, blood glucose or intramuscular triglyceride [26]. 
Glycogen serves as a form of energy storage in liver and to some extent, in muscle. When 
energy intake is higher than the metabolic demand, extra glucose molecules can be stored as 
glycogen. Alternatively, the adipose tissues are the storage site for excess FAs, in the form of 
fat [27]. 
1.2.2 Glycolysis pathway 
ATP is generated both in the cytosol and mitochondria. In the cytosol, the glycolysis, also 
known as Embden–Meyerhof pathway converts glucose into pyruvate via a 10-step process. 
The net yield of this enzymatic process is 2 molecules of pyruvate, 2 molecules of ATP, and in 
addition two NADH (reduced nicotinamide adenine dinucleotide)  per molecule of glucose [3]. 
The net reaction of glycolysis can be written as: 
Glucose + 2 NAD+ + 2Pi + 2 ADP → 2 Pyruvate + 2 NADH + 2H+ + 2 ATP +2 H2O  
The glucose utilized in this process is mobilized from intracellular glycogen or transported 
from the bloodstream into cytosol through glucose transporters (GLUTs). The GLUT family 
transporters are subdivided into three classes and the physiological role of class I GLUT 
(GLUT1 to GLUT4) is associated with facilitating glucose transport into insulin-sensitive cells 
[28]. However, how the produced pyruvate will be utilized, depends on the level of oxygen 
present. In the presence of oxygen (aerobic condition), pyruvate is transported to the 
mitochondrial matrix to be oxidized in the TCA cycle. Under anaerobic condition (low or no 
oxygen), pyruvate is primarily converted to lactate by lactate dehydrogenase, and NADH is 
oxidized to NAD+ [3, 29]. A detailed description of the glycolysis pathway is depicted in Figure 
1.3. 
The flux through glycolysis must be regulated to meet cellular demand depending on the 
condition both inside and outside of the cell. In general, enzymes that catalyze essentially 
irreversible reactions would be expected as potential sites of control. In glycolysis, hexokinase, 
phosphofructokinase, and pyruvate kinase, are considered to have regulatory roles since the 
three reactions they catalyze are virtually irreversible. Their activities are allosterically 





Figure 1.3 The series of chemical reactions in the glycolysis pathway. Each step is catalyzed 
by an enzyme and the three irreversible reactions in the pathway are circled blue. The net yield 
after the 10-step glycolysis pathway is 2 ATP, 2 NADH and 2 pyruvates. Figure based on [3] 
 
1.2.3 Tricarboxylic acid cycle 
The tricarboxylic acid (TCA) cycle, also known as citric acid cycle or Krebs cycle is a series 
of biochemical reactions that occurs in the mitochondrial matrix and is a central hub for aerobic 
energy metabolism. The cycle produces intermediates to be used in macromolecular synthesis 
and harvest high-energy electrons from carbon fuels to form NADH and FADH2 (reduced 
flavin adenine dinucleotide). The NADH and FADH2 that are produced throughout the cycle 
serve as electron donors for downstream cellular processes such as ETC to produce ATP [32, 
33].  
The common fuel for feeding the TCA cycle is acetyl-coenzyme A (acetyl-CoA) and pyruvate 
is a major source of acetyl-CoA in this cycle. After glycolysis, pyruvate is transported from the 
cytosol to mitochondrial matrix by mitochondrial pyruvate carrier (MPC, heterocomplex of 
MPC1 and MPC2), located in the inner mitochondrial membrane [34]. Inside the mitochondrial 
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matrix, pyruvate is primarily oxidized to acetyl-CoA by pyruvate dehydrogenase (PDH), also 
generating an NADH and a CO2 in the process. PDH is highly regulated and thus control the 
flux of glycolytic acetyl-CoA into the TCA cycle (see section 1.4.1). Acetyl-CoA then fuses 
with oxaloacetate with the help of citrate synthase, to produce the first product of the classical 
8-step cycle, citrate (a type of tricarboxylic acid, hence the name tricarboxylic acid cycle) [3, 
35]. Figure 1.4 illustrates the full oxidation of acetyl-CoA through the 8-step process. 
 
 
Figure 1.4 Biochemical reactions that drive TCA cycle. Acetyl-coA is the typical input of this 
cycle which condenses with oxaloacetate to form citrate with the help of citrate synthase and 
eventually oxidized in 8 consecutive reactions. In step 2, the mitochondrial aconitase make isocitrate 
which is then converted by isocitrate dehydrogenase to α-ketoglutarate with the production of 1 
NADH (step 3). α-ketoglutarate dehydrogenase further catalyzes the conversion of α-ketoglutarate 
to succinyl Co-A and a second NADH in step 4. The step 5 produce succinate catalyzed by succinyl-
CoA synthetase as well as 1 GTP is produced from 1 GDP.  The conversion of succinate to fumarate 
by succinate dehydrogenase produce 1 FADH2 in the process during step 6. Fumarase converts 
fumarate to malate and in the final step, malate dehydrogenase transform malate to oxaloacetate 
with the production of another NADH. Oxaloacetate further starts the cycle. The enzymes are shown 
in blue circles, the intermediate metabolites in black and the GTP, H2O, and the electron donors, 
NADH and FADH2 produced are marked as green. [35, 36]. Figure based on [37]   
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However, pyruvate is not the only source of acetyl-CoA, it can be generated from β-oxidation 
of FAs or from ketogenic amino acids. For example, glutamine is the most abundant non-
essential amino acid in the human body, which enters the TCA cycle in the form of α-
ketoglutarate [32]. The cycle produces 3 NADH, 1 FADH2, and 1 guanosine triphosphate 
(GTP) from 1 molecule of acetyl-CoA [35]. Since, one glucose molecule ends up in two 
pyruvates along with 2 NADH and 2 ATP after glycolysis; the net yield of this whole journey 
after complete mitochondrial oxidation is 10 NADH, 2 FADH2, 2 GTP, and 6 CO2. The key 
control points involved in the regulation of the TCA cycle are the allosteric enzymes isocitrate 
dehydrogenase and α-ketoglutarate dehydrogenase. The activity of these two enzymes are 
affected by the concentration of ATP and NADH. Isocitrate dehydrogenase is inhibited by 
NADH by directly displacing the NAD+. α-ketoglutarate dehydrogenase is inhibited by the 
products of the reaction it catalyzes, succinyl CoA and NADH. In addition, both of these 
enzymes are inhibited by ATP; when the cell has a high level of ATP, the rate of the cycle is 
reduced. 
1.2.4 Mitochondrial electron transport chain and oxidative phosphorylation 
Oxidation/reduction reactions in the TCA cycle produce reduced electron carriers in the form 
of NADH and FADH2, which serve as electron donors to the ETC, located in the IMM. The 
oxidation of these carriers is coupled to ATP generation by the OXPHOS system [38]. 
OXPHOS involves transport of electrons through the ETC to the final electron acceptor, 
molecular oxygen (O2) and phosphorylation of ADP to form the universal high energy 
molecule, ATP. The ETC is made up of four protein complexes, commonly known as complex 
I-IV coupled to a phosphorylating complex, the ATP synthase (complex V) (see Figure 1.5). 
NADH coenzyme Q reductase (complex I) receives electrons from NADH and transfers to 
coenzyme Q (Co-Q, reduced form of ubiquinone). Succinate dehydrogenase (complex II, a part 
of TCA cycle) also transfers electrons to Co-Q that is received from FADH2. Electrons are 
shuttled from Co-Q via cytochrome C oxidoreductase (complex III) to cytochrome C (Cyt C). 
Cyt C is located at the cytosolic side of the respiratory chain and is responsible for further 
transport of electron to cytochrome C oxidase (complex IV).  Cytochrome C oxidase is the last 
enzyme of the ETC and transfers a pair of electrons to molecular O2 where it is reduced to form 
H2O [39]. 
Complex I, III and IV function as proton pumps. For every pair of electrons transported, 
complex I and III each extrudes two pairs of protons; while complex IV pump out one pair of 
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protons from the mitochondrial matrix into intermembrane space. As protons accumulate, they 
establish an electrochemical proton gradient (membrane potential), representing a 
protonmotive force (PMF). The potential energy stored in the PMF is then harvested by the 
ATP synthase, which drives the energetically favorable flux of protons back into the matrix. 
The energy released in this process enables conversion of ADP to ATP [40, 41]. The net 
production of ATP is around 32 molecules from the catabolism of one glucose molecule [38], 
however the overall yield might be influenced by the mitochondrial membrane integrity or 
effects of uncoupling proteins. 
 
Figure 1.5 Bioenergetics of the ETC and OXPHOS system. Electrons from NADH and 
FADH2 are shuttled to complex I and II, and are transported throughout the ETC. Transfer 
of electrons pump out protons from the matrix into the IMS through complex I, III and IV, 
thereby creating a proton gradient. This gradient drives the ATP synthase to flux protons 





1.2.5 Fatty acid transport and oxidation  
Fatty acids are energy rich molecules and yield the most ATP as energy per gram basis. 
Therefore, FAs are the foremost storage form of fuel in animal cells and are involved in the 
formation of biomolecules (e.g triglycerides, phospholipids, ketone bodies) and in signaling 
pathways. They regulate countless metabolic pathways by acting as ligand for peroxisome 
proliferator nuclear receptors (PPARs) [43]. 
Due to the hydrophobic nature of FAs, they are co-transported as bound to albumin in the 
circulation [44]. Upon release by lipoprotein lipases, FA  primarily enter the cell with the help 
of specific transporters on the cell surface, such as cluster of differentiation 36 (CD36) [45]. 
Once inside the cell, the FAs are activated by long chain acyl-CoA synthetases (ACS) which 
conjugates a coenzyme A (CoA) to the FA forming acyl-CoA.  
Catabolism of FAs to produce energy generally takes place in mitochondrial matrix via β -
oxidation. Hence, the enzyme carnitine palmitoyltransferase-1 (CPT1), present in the inner 
surface of the OMM, converts acyl-CoA to acyl-carnitine. CPT1 is the rate-limiting enzyme 
and is inhibited by malonyl-CoA, a precursor of FA biosynthesis, thus provides a major site of 
regulation of mitochondrial FA import [46, 47]. The fatty acyl-carnitine moiety is then 
transported across the IMM by the transport protein carnitine translocase (CAT). Inside the 
matrix, acyl-carnitine is converted back to acyl-CoA, by CPT2, and is then ready to be utilized 
in the β-oxidation pathway [48]. 
β-oxidation is a process in which an acyl-CoA ester undergoes a repetitive 4-steps reaction 
cycle involving dehydrogenation, hydration, another dehydrogenation and thiolytic cleavage 
[49]. The acyl-CoA is shortened by two carbons in each oxidation cycle, and ultimately results 
in release of NADH, FADH2, and acetyl-CoA [50]. The acetyl-CoA produced then enters TCA 
cycle and are used by the ETC to produce energy. Thus, complete oxidation of a 16-carbon 
palmitic acid (PA) will yield eight molecules of NADH, FADH2, and acetyl-CoA each; giving 
rise to up to 120 ATP molecules, through complementary actions by the TCA cycle and 
OXPHOS system. 
1.3 Cellular stress and metabolic adaptation to stress 
Cells, either growing in vivo or in vitro are exposed to various external and internal stimuli 
which may induce stress. Some of the conditions that may result in cellular energy stress are 
mutation, metabolic disease, temperature changes endurance exercise, ROS damage, caloric 
restriction, excessive nutrient uptake, hypoxia etc. Such stressors can damage intracellular 
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components including DNA, RNA, protein and lipids. At the same time, stressors can trigger 
different rescue responses in the cell depending on the level of insult and duration of the stress. 
They activate a variety of defense and pro survival mechanisms to re-establish the homeostasis 
by 1. Inducing repair mechanism, 2. Mechanisms that result in temporary metabolic adaptation, 
3. Inducing autophagy, or 4. Triggering cell death. The rescue capacity of a cell depends on the 
flexibility of involved pathways and is a major determinant of its fate [51, 52].  
1.3.1 Metabolic flexibility 
Metabolic flexibility is the ability of an organism to respond or adapt to conditional changes in 
metabolic energy supply and demand. This concept has been promulgated primarily in the 
context of mitochondria to select fuel between glucose and FAs. Several tissues such as the 
liver, adipose tissue, skeletal muscle and heart systematically govern metabolic flexibility via 
sensing, uptake, transport, expenditure and storage of nutrients by maintaining communication 
at the endocrine level. Exercise is another physiological condition that can alter fuel 
consumption to meet increased energy demand depending on the duration and intensity of the 
exercise [4, 53]. A study on fuel selection of skeletal muscle in lean and obese individuals 
revealed a remarkable example of metabolic flexibility [54]. After overnight fasting, the 
skeletal muscles of lean individuals increased FA uptake and oxidation, however, insulin-
stimulated conditions showed suppressed FA condition and increased glucose uptake, 
oxidation and storage displaying remarkable metabolic flexibility. Insulin-resistant obese 
patients did not show increased FA oxidation after fasting or reduced FA oxidation upon insulin 
infusion [55], reflecting metabolic inflexibility. Such inability to alter fuel oxidation in 
response to changes in nutrient availability has been implicated in insulin resistance, type 2 
diabetes, mitochondrial dysfunction and obesity related complications [4].  
1.3.2 Molecular mechanisms of metabolic adaptations and stress responses  
Molecular mechanisms facilitating metabolic adaptations to energy stress include the activation 
of the energy sensor, AMP-activated kinase (AMPK). As a stress sensor, AMPK turns on a 
metabolic shift towards mitochondrial oxidation that generate ATP, while inhibiting anabolic 
pathways involving biosynthesis and proliferation that consume ATP [56]. Glucose-expending 
therapies such as exercise and caloric restriction also induce an energy challenge that lead to 
the activation AMPK. Other upstream activators of AMPK are Liver Kinase B1 (LKB1) and                                                                                                                                                                                                                                                                                                                                                                                          
Ca2+/calmodulin-activated protein kinase (CAMKK) that trigger AMPK activation in response 
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to increased intracellular Ca2+ levels [57].  AMPK also induce autophagy in response to stress 
through a ‘dual-safe’ mechanism that involves inactivation and direct phosphorylation of 
mTORC1 and ULK1 protein kinase respectively [58]. 
Response to oxidative stress (e.g reactive oxygen species or ROS damage) activates enzymatic 
antioxidant defense via ROS-metabolizing enzymes including glutathione peroxidase, catalase, 
and superoxide dismutase (SOD). Some exogenous antioxidants such as Vitamin A, C, and E 
found in foods also act as free-radical scavengers. Other responses such as heat shock response 
or unfolded protein response (UPR) mediate an increased chaperon protein activity that 
improves the protein folding capacity of the cell, thus counteract the stress and promote 
survival [51, 59].  
However, if the level of stress is very severe or prolonged and the condition goes unresolved, 
such an unhealthy energy balance may have systemic effects on energy storage and utilization, 
and this can lead to the potential harmful secondary effects. Some examples of cellular energy 
failure include decreased membrane potential of mitochondria, intracellular accumulation of 
Ca2+ or Na+, increased lactate concentration, excess ROS production and aerobic glycolysis 
[51, 60] . Aerobic glycolysis, which primarily has been characterized in cancer cells (Warburg 
effect), is a condition in which glucose is converted to lactate with increased rate of glycolysis 
even in the presence of oxygen [61]. The activation of oncogenic serine/threonine kinase, Akt 
supports aerobic glycolysis by promoting glucose dependency of the cells. Akt has also a role 
in preventing autophagy by interacting with the mammalian target of rapamycin (mTOR) [62]. 
Akt activation is an important mediator of insulin induced signaling and can also enhance 
glycolytic flux by increasing GLUT1 expression [63]. The increased Akt activity has been 
reported in many human cancers. Therefore, the Akt/mTOR/AMPK network is one of the 
major signaling pathways that is associated with cellular energy stress and metabolic flexibility 
[62, 64]. 
Besides, excess ROS production contribute to early aging and causes DNA mutation that 
promote tumorigenesis. Moreover, accumulation of peroxidized polyunsaturated FAs, ROS, 
mutation damaged protein or altered glycosylation etc. lead to the aggregation of 







1.4 Biological and pharmacological modulators of cellular energy metabolism 
Modulation of cell metabolism may occur through interactions of enzymes and other proteins, 
co-factors and molecular energy sensors, and can to some extent be targeted by 
pharmacological agents (e.g DCA, rotenone) [65].  Regulators of energy metabolism control 
vital parts or components of metabolic pathways and function as nodes in rewiring of 
metabolism. In fact, the concept of modulation is to improve or optimize energy metabolism 
either by shifting metabolism towards a preferred substrate or by improving mitochondrial 
coupling or stimulating glucose oxidation. The following section lists some of the key 
modulators of energy metabolism and the mechanisms of their actions. 
1.4.1 Pyruvate dehydrogenase (PDH) and Pyruvate dehydrogenase kinases (PDKs) 
The PDH complex is a multi-enzyme complex in mitochondria that catalyzes the irreversible 
oxidative decarboxylation of pyruvate. It is a mitochondrial enzyme that connects glycolysis 
to the TCA cycle, as it controls the conversion of pyruvate, Coenzyme A (CoA) and NAD+ 
into acetyl-CoA, NADH and CO2. The acetyl-CoA produced, along with the acetyl-CoA 
coming from FA oxidation, amino acids and ketone bodies are utilized in the TCA cycle to 
produce fuel for mitochondrial respiration  [54, 66]. 
PDH complex has three different catalytic components: E1, pyruvate dehydrogenase that 
catalyzes the decarboxylation of pyruvate; E2, transfers the acetyl groups to CoA to form 
acetyl-CoA; E3, catalyzes the oxidation of lipoyl moieties on E2 with concomitant reduction 
of NAD+ [67].  
PDH is more active when the cells are healthy and in well-fed state. However, suppression of 
PDH activity is crucial during nutrient depletion when glucose is not available. During fasting 
or insulin resistant state, the PDH activity is tightly controlled by the upregulation of pyruvate 
dehydrogenase kinases (PDKs) that phosphorylate specific serine residues in the alpha-subunit 
of the E1 enzyme, resulting in inhibition of PDH complex  (see Figure 1.6) [68]. Therefore, 
PDKs are important modulators of metabolism, acting as a gatekeeper enzyme of glucose 
oxidation [69]. Four mammalian isoforms of PDK (1 to 4) have been identified so far and they 
have tissue specific expression and different phosphorylation target sites. PDK1 is ubiquitously 
expressed and is the principle enzyme that regulate hepatic PDH [70]. PDK2 and PDK4 are 
widely distributed in tissues like kidney, heart, and liver in humans and rodents. PDK4 is also 
highly expressed in tissues that have high glucose and fatty acid oxidation rate such as skeletal 
muscle [54, 71]. PDK3 is the kinase regulating PDH activity in kidney, brain and testes [70, 
14 
 
72]. PDH inhibition can be counteracted by reciprocal dephosphorylation of E1α subunit by 
two pyruvate dehydrogenase phosphatases (PDP1 and PDP2). PDKs are downregulated in the 
presence of insulin, Ca2+ and inhibitors and their activity can be transcriptionally regulated via 
signaling cues such as PPAR-α, AMPK and hypoxia inducible factor 1 (HIF1) [73]. 
 
 
Figure 1.6 Regulation of pyruvate dehydrogenase complex (PDH) and physiological 
factors involved in regulating pyruvate dehydrogenase kinase (PDK1-4) activity.  
The PDH complex consists of three components: pyruvate dehydrogenase (E1), dihydrolipoyl 
acetyltransferase (E2), and dihydrolipoyl dehydrogenase (E3). Pyruvate dehydrogenase (E1) 
catalyzes decarboxylation of pyruvate into acetyl-coA. Phosphorylation of E1 by PDK1-4 
inactivates E1, and subsequently the whole complex. This inactivation is reversed via 
dephosphorylation of E1 by pyruvate dehydrogenase phosphatase (PDP). Adapted from [68]. 
 
1.4.2 Pharmacological inhibitors of PDK 
An elevated expression of PDK has been reported in many cancers that cause a shift in the 
glucose metabolism towards glycolysis over OXPHOS, a phenomenon called ‘Warburg effect’, 
described by Otto Warburg in 1924 [69]. This term is synonymously exchanged with aerobic 
glycolysis (described in section). Although this process is less energy efficient, glycolysis is a 
rapid process that provide cancer cells potential advantages over OXPHOS to cope with 
environmental constraints, including hypoxia [74]. Therefore, targeting PDK can provide 
potential therapeutic benefits for developing new cancer therapies [69, 75]. The known PDK 
inhibitors act by binding to one of the four binding sites: 1. A pyruvate binding site, 2. An 
allosteric site, 3. A nucleotide binding site, and 4. A lipoamide binding site. The naturally 
occurring PDK inhibitors are pyruvate, NAD+, and CoA which activate PDH by inhibiting 




inhibitor of PDK. DCA can penetrate membranes and is rapidly absorbed, it can also readily 
cross the blood brain barrier. PDK isoforms have a conserved pocket, mainly pyruvate-binding 
site to which DCA binds. PDK2 is the most sensitive to DCA, PDK1 and PDK4 are equally 
sensitive whereas PDK3 is the least sensitive [76]. To inhibit PDK, DCA concentration ranges 
between 10-250 μM in physiological level, when taken orally. But in contrary to the 
physiological point of view, in vitro studies involving immortal cell lines require very high 
concentration of DCA (may be up to 100 mM) [66]. Other known PDK inhibitors include PS-
10, Betulinic acid (BA), Phenylbutyrate and some derivatives of DCA such as Mito-DCA and 
Mitaplatin [71]. 
1.4.3 Uncoupling proteins 
Uncoupling proteins (UCPs) are important modulator of metabolism as they uncouple 
respiration from ATP synthesis by mediating a regulated discharge of proton gradient into the 
matrix. Thus, the typical result will be dissipation of the mitochondrial membrane potential and 
reduced ATP yield [77]. UCPs are the transporters of IMM and have functions in 
thermogenesis, reduction of ROS production or maintaining redox balance. There are five UCP 
homologs in mammal; among them, UCP1-UCP3 are related, while UCP4 and UCP5/BMCP1 
have more distant relationship. Each of them has a molecular mass of 31-34 kDa and the 
functional carrier protein is a homodimer [78]. UCP1 is predominantly expressed in brown 
adipose tissue (BAT) where it can mediate cold-induced thermogenesis. UCP2 is expressed in 
different tissues and is involved in diet-induced thermogenesis as well as regulation of glucose 
homeostasis. UCP3 is mainly present in skeletal muscle, but also found in BAT and heart 
tissue. UCP3 is thought to have a role in mitochondrial fatty acid oxidation and regulating 
ROS-induced oxidative damage [79, 80]. 
1.4.4 Respiratory inhibitors and uncouplers 
Inhibitors of ETC are substances that bind to specific components of the ETC and block their 
ability to reversibly change from an oxidized state to reduced state. Inhibition of mitochondrial 
ETC lead to autophagy-induced cell death through the generation of ROS [81]. Hence, in terms 
of oncogenic signaling, inhibition of mitochondrial respiration could provide therapeutic 
benefit for certain targeted therapies. Further, experimental and clinical procedures involving 
mitochondrial inhibitors and manipulators might give insights where the potential disturbance 
is located [82]. For experimental purposes, amytal, rotenone, antimycin A, sodium azide, 
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myxothiazol and cyanides are the most common inhibitors of ETC, and carbonyl cyanide m-
chlorophenyl hydrazone (CCCP), p-trifluoromethoxyphenyl hydrazone (FCCP), phenol SF 
6847, and hydrophobic salicylanilide S-13 are used as uncouplers (See Figure 1.7) [83, 84]. 
Oligomycin is the inhibitor of ATP synthase that prevents protons from passing back into the 
mitochondria required for ATP production by blocking its proton channel (f0 subunit) [85]. 
CCCP or FCCP uncouple mitochondrial respiration from ATP synthesis by permitting 
transport of protons across the membrane leading to the depolarization of membrane potential 
that results in increased oxygen consumption but no ATP production. Rotenone and antimycin 
A are the inhibitors of complex I and III respectively, that block passage of electrons through 
these complexes. So, the addition of both these inhibitors results in no further electron transfer 
through the ETC [83, 86]. Azides and cyanides act on respiratory chain by inhibiting the heme 
groups of cytochrome oxidase (Complex IV) [84]. 
 
Figure 1.7 Modulators of the ETC. Rotenone inhibits ETC-Complex I, antimycin A inhibits 
ETC Complex III, oligomycin targets the ATP synthase (Complex V) and FCCP targets the 
IMM to enable proton flux across the membrane by disrupting the membrane potential. 
Adapted from [87] 
 
1.5 Metabolism and disease 
Occurrence of metabolic disorders is often associated with loss of mitochondrial function. 
Mitochondrial dysfunction has been implicated in a number of human diseases including 
cancer, cardiovascular diseases, epilepsy, neurodegenerative diseases, aging etc. Dysfunctional 
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mitochondria also found to have important role in the pathogenesis of chronic metabolic 
diseases characterized by insulin resistance in obesity and type-2 diabetes. These disorders 
arise from either dysfunction in the mitochondrial complexes or mutation in the mtDNA or 
nuclear DNA [88-90]. Defects in transferring of electrons out of the membrane cause electron 
accumulation in the ETC complex that allows binding of electrons to free oxygen to produce 
ROS, which contributes in pathologies like cancer, degenerative diseases and aging. Besides, 
excess energy intake may reduce lipid oxidation and increase ectopic lipid storage in the cells 
that lead to insulin resistance [90]. 
1.5.1 PDH dysregulation in diseases 
PDH dysregulation is involved in severe disease conditions including cancer, neurological 
dysfunction, lactic acidosis, diabetes or other insulin-resistant states, growth retardation and 
even early death. PDH complex deficiency is itself a type of metabolic disease where the body 
lack the ability to break down foods to be used for producing energy and symptoms include 
lethargy, poor feeding and fast breathing [71, 91]. Fluge Ø et al suggested PDH impairment in 
Myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) patients after analysis of blood 
serum from 200 ME/CFS patients and 102 healthy individuals [73]. Furthermore, PDH 
deficiency has been demonstrated in metabolic disorders that are caused by mutations, for 
instance in cancer. Stable overexpression of HIF1α and oncogenic Myc play an important role 
in the upregulation of glucose transporter GLUT1, all PDKs and glycolysis enzymes favoring 
the Warburg effect [71]. Interestingly, at least one of the PDK isoforms are found to be highly 
expressed with excess production of lactate in the cells with pathological conditions due to 
PDH impairment. For instance, involvement of increased PDK2 mRNA in glioblastoma [54]. 
Another study of hyperthyroidism involving rat heart emphasized increased ex vivo activity of 
PDK while PDH-mediated glucose oxidation was inhibited [92]. In primary biliary cirrhosis, a 
condition of autoimmune disease, PDH complex is the target for antimitochondrial 
autoantibodies, leading to inflammation and tissue destruction [73]. 
1.5.2 Metabolic rewiring in cancer  
Metabolic rewiring, also known as metabolic reprogramming or remodeling is common in 
many pathological and physiological processes including stem cell formation, epithelial-to-
mesenchymal transition (EMT), cancer progression and immune responses [93]. Rewiring of 
metabolism is a common event in cancer cells to promote survival, growth, proliferation and 
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long-term maintenance [94]. Vander Heiden et al. suggested that oncogenic mutations evade 
the need of stimuli for nutrient uptake and result in increased uptake of nutrients, particularly 
glucose [95]. This can be exemplified by the enhanced GLUT expression in several cancers 
due to the activation of certain oncogenes such as ras, c-myc, src, and  transcription factors like 
HIF-1α [96]. Therefore, cancer cells preferentially increase the rate of aerobic glycolysis over 
OXPHOS, and this kind of metabolic rewiring has currently been recognized as a hallmark of 
cancer [74]. It also promotes glycolysis-branched pentose phosphate pathway (PPP) to produce 
nicotinamide adenine dinucleotide phosphate (NADPH), required for the impairment of ROS; 
thereby sustaining tumor cell survival and signaling [74, 97]. 
Deregulation of few metabolic enzymes has been reported in some cancers. Repeated 
upregulation of Hexokianse II has been implicated in increased glycolytic rate and inhibition 
of apoptosis [98, 99]. Loss of function mutations in two tumor suppressors, succinate 
dehydrogenase (SDH) and fumarate hydratase (FH), the TCA cycle enzymes lead to 
tumorigenesis through the activation of HIF signaling [100].  
At the early stage of cancer progression, cells degrade the ECM by increasing motility and 
invasion abilities. These processes are energetically costly and are supported by the remodeling 
of cell–cell and cell-ECM interactions, activation of EMT, and rearrangements of focal 
adhesions [74, 101]. Similarly, immune cells also modify their metabolic requirements to 
activate their host-defense mechanisms against stress. For example, lymphoid cells undergo a 
metabolic switch from OXPHOS-dependent catabolic state to a glycolysis-dependent anabolic 















1.6 Aim of the study 
Our major aim was to characterize changes in key metabolic and physiological functions in 
cultured cells upon experimental manipulation of PDH activity. Our strategy was to mimic 
relevant metabolic defects and changes in glucose supply in cultured cell models to investigate 
which type of signals or features the cell displays under given metabolic defects.  
The study particularly focused on manipulating PDH function by inducing upregulation of 
PDKs in cultured cells. Besides, stress-inducing metabolic environment (glucose restriction), 
direct intervention of metabolic pathways (addition of enzymatic inhibitors, metabolic 
stressors, mitochondrial uncoupling) was also applied to investigate effects on cell proliferation 
and metabolism. The specific aims are listed below: 
 
A. To characterize proliferation and metabolism in cell lines overexpressing PDK1, 
PDK2, PDK3, and PDK4. 
B. To characterize mechanisms of metabolic adaptation in PDK overexpressing cells 
under different conditions of energy stress1 
















                                                          
1 Part of the data generated from this study has been included in a manuscript under review for 
publication in Mitochondrion (Pettersen et al, revised version). 
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2 Materials and methods 
2.1 Cell line 
The cell line that was used in this study was a human immortalized triple negative breast cancer 
cell line, the MDA-MB-231. The cell line had previously been transduced to overexpress the 
four isoforms of PDK by Lena Hansen in Professor Karl Johan Tronstad’s laboratory. Thus, 
there were four different cell lines overexpressing PDK1, PDK2, PDK3, and PDK4, as 
confirmed by qPCR.  I participated in the transduction procedure to establish my own cells but 
was not successful to transduce all four PDK isoforms, therefore, I continued my project with 
the cell lines made by Lena Hansen. The parental line (Wild type) was used as a control. They 
are referred to as 231 WT, 231 PDK1, 231 PDK2, 231 PDK3, and 231 PDK4 throughout the 
study. 
 General maintenance and culture conditions 
The cells were cultured in high glucose Dulbecco’s modified eagle’s medium; DMEM (Cat no. 
D5671, Sigma) supplemented with 10% hi FBS (Heat inactivated Fetal Bovine Serum, Cat no. 
A15-101, PAA), 1% Pen-Strep (10,000 units penicillin + 10 mg streptomycin per ml, Cat no. 
P0781, Sigma) and 0.5mM L-glutamine (Cat no. G7513, Sigma), thereby making complete 
DMEM (cDMEM). Media with different concentration of glucose, high (25 mM), moderate (5 
mM), and low (1 mM) were prepared from 2.5 M glucose stock (Sigma-Aldrich) in glucose 
free 1X Gibco™ DMEM (Cat no. 11966-025, ThermoFisher scientific) supplemented with 
10% hi FBS and 1% Pen-Strep, as required by different experiments. 
The cells were routinely handled in a clean lamina flow hood to maintain sterility and checked 
under a Nikon ECLIPSE TS100 microscope to monitor confluency. They were cultured in 75 
cm2 T75 flasks to 80-90% confluence before splitting to new flask, or to 10 cm dishes for RNA 
and protein extraction. All the cultures were maintained at a Hera cell 150 (Heraeus) incubator 
with a humidified atmosphere of 5% CO2 in air at 37 °C. 
2.1.1 Thawing of cells 
Complete culture medium was preheated in a 37°C water bath before the cryo-preserved cells 
(see details in section 2.1.5) were taken out from the nitrogen-tank. The vials were wiped with 
70% alcohol and transferred to the laminar air hood. For thawing, 500 μl preheated cDMEM 
was added to each vial and mixed gently by pipetting. T75 culture flasks were prepared with 
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10 ml of preheated cDMEM and labelled before the cells were transferred from the 
corresponding cryo vial. The medium was replaced with fresh medium the next day. The cells 
were kept growing in the Hera cell 150 (Heraeus) incubator until they reach 80% confluency. 
2.1.2 Propagation of cells 
The cells were routinely passaged every 2-3 days when a culture reached 80-90% confluence. 
cDMEM, 1X PBS (Phosphate buffered saline, prepared from tablets Cat no. P4417, Sigma 
dissolved in MilliQ-H2O) and Trypsin-EDTA solution (0.25%, Cat no. T4049, Sigma) were 
preheated to 37°C for 30 minutes in a water bath. A vacuum pump was used to remove the old 
medium from the culture flasks and the cells were gently washed with PBS. 3 ml trypsin-EDTA 
was added to each flask and incubated for 2-3 minutes to allow trypsin to break down the 
proteins that enable the cells to adhere to the culture flasks. The cells were observed under a 
light microscope to see if they were floating or not, otherwise the side of the flasks were gently 
tapped for complete detachment of the cells. 5 ml of warm cDMEM was added to neutralize 
trypsin activity and the cell suspensions were transferred to 15 ml tubes. The tubes were 
centrifuged at 1200 rpm for 5 minutes and the supernatants were carefully removed. The cell 
pellets were resuspended in fresh media and split 1:4 into new T75 flasks containing 10 ml of 
fresh cDMEM. The flasks were put back into the incubator. 
2.1.3 Cell counting and determination of viability 
Counting of the cells was important to prepare a definite number of cells depending on the 
experiment. A hemacytometer from Reichert Bright-Line (#1490) was used to count the cells 
when the cell concentration was low. But mostly, a Countess automated cell counter from 
Invitrogen was used to count the cells. This instrument makes use of a trypan blue exclusion 
test which is based on the principle that viable cells exclude this dye due to intact cell 
membrane whereas dead cells do not [102]. The counting procedure involves mixing 10 µl of 
cell suspension with 10 µl of trypan blue before transferring 10 µl of this mixture to a Countess 
cell counting chamber slide. The slide is then inserted into the allotted slot on the front of the 
machine. Upon pressing the start button, the counting starts and data including total, live, and 
dead cell count, and percent viability appears on the screen. The counting usually takes less 




2.1.4 Freezing of cells 
Long term storage requires freezing the cells and preserving them in liquid nitrogen. After 
reaching 70-90% confluency, they were washed with PBS, trypsinized (as previously described 
in 2.1.3) and centrifuged at 1200 rpm for 5 min. The pellets were resuspended in freezing 
medium (10%v/v DMSO (Cat no. D5879, Sigma), 20%v/v hi FBS and 70%v/v cDMEM and 
kept on ice. 1.5 ml of each cell-freezing medium suspension was carefully aliquoted into small 
CryoTubeTM vials (#363401, Nunc). The vials were labeled with cell line names, passage 
number and date and then put into an isopropanol freezing box. The box was stored in -80°C 
overnight to have a smoother transition of temperature change by lowering the temperature 
1°C/min. The day after, the cells were transferred from the -80°C freezer to a tank containing 
liquid nitrogen for long-term storage. 
2.2 PDK overexpression in MDA-MB-231 cells by retroviral transduction  
Four Moloney murine leukemia virus (MMLV) derived retrovirus gene expression vectors 
containing each of the four PDK cDNAs and one antibiotic resistance genes were transfected 
in HEK293 derived Phoenix-AMPHO (ATCC® CRL-3213™) packaging cells by 
Lipefectamin-200 transfection. The antibiotic resistance genes were puromycin, hygromycin, 
gentamycin, and blasticidin for PDK1, PDK2, PDK3, and PDK4 respectively. This transfection 
procedure was performed in Haukeland University Hospital, Bergen. Therefore, the 
experimental details are not explained for the transfection process. 
The transduction of MDA-MB-231 cells by Phoenix packaging cells was done in Prof. 
Tronstad’s laboratory. For retroviral infection, 1.5 x106 Phoenix cells were seeded in T75 flask 
containing cDMEM followed by 48 hours of incubation until they reach ~80% confluency. 
MDA-MB-231 cells were seeded in the same cDMEM in 6-well plates with a seeding density 
1x105. The next day, the virus-containing medium was collected from the Phoenix cells and 
filtered through a 30ml syringe with a 0.2μm Whatman filter. Protamine sulfate (5 µg/ml, #P-
4020) was added, which aids the virus to penetrate the membranes. The media of the target 
cells were aspirated and replaced with virus-containing medium (1 ml/well) and left until the 
next day as reverse transcription and integration of the construct takes place between 24-36 h. 
The following day, the virus medium was replaced by cDMEM and the cells were transferred 
to 10 cm dishes, allowing the cells to proliferate. All equipment that came in contact with virus 




2.2.1 Selection of the transformed cells 
72 h post infection, the cells were ready for selection. The old media were replaced with new 
cDMEM and respective selection antibiotic was added in minimal concentration since too high 
concentration of the selective agent can inhibit growth of cells. Upon everyday monitoring, the 
concentrations were gradually increased to final concentrations of 1.5 µg/ml puromycin, 175 
µg/ml hygromycin, 1 mg/ml gentamycin and 10 µg/ml blasticidin. The dead non-transformed 
cells were floating in the media that was replaced every 2/3 days with new media and selection 
antibiotics. Selection process continued to 15/16 days and finally very few transformed cells 
were left in the dishes. They were transferred to new dishes with fresh media and kept growing 
until confluent. Re-selection of the cells was done at different time points throughout the study 
period to make sure the overexpression still exists in the cell pool. 
2.2.2 Preparation of cells for RNA and protein extraction 
Equal number of 231 WT and PDK1-4 transduced cells were seeded in 10 cm petri dishes and 
were grown for 2/3 days to reach 80-90% confluency. After removing the media, the cells were 
washed with warm PBS. The PBS was aspirated, and the cells were gently scraped in 1 ml cold 
PBS and transferred to 1.5 ml Eppendorf tubes. The dishes were again washed with 0.5 ml cold 
PBS and the contents transferred to the same tubes. The tubes were centrifuged at 1200 rpm 
for 8 min. The supernatant was removed, and the cell pellets were preserved at -80°C freezer 
for RNA and protein extraction in future. 
2.3 Analysis of PDK overexpression by RT-PCR 
2.3.1 RNA isolation 
Qiagen RNEasy Mini Kit was used to extract total RNA by following the manufacturer’s 
protocol. Cell pellets were taken out from the -80°C freezer and loosen thoroughly by flicking 
on the tubes. 700 μl of buffer RLT was directly added to lyse the cells and mixed well by 
pipetting. Equal amounts (700 μl) of 70% ethanol was added to homogenized lysates and mixed 
well by pipetting. 700 μl of each sample was transferred to a RNeasy spin column placed in a 
2 ml collection tube and was spun for 30 s at 8000 rpm. The flow-through was removed and 
the remaining 700 μl sample was added to the same column and the same procedure repeated. 
The RNA was bound to the spin column which was then washed with 350 μl buffer RW1 and 
spun for 30 s at 8000 rpm, the flow-through discarded. In a separate tube, 10 μl of DNase I 
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Enzyme was added with 70 μl of buffer RDD, mixed gently by inverting the tube and this 
DNase I incubation mix (80 μl) was directly added to the spin column membrane and left on 
the benchtop for 15 min. Again, the bound RNA was washed with 350 μl of buffer RW1 
followed by spinning for 30 s at 8000 rpm. The next wash was done with 500 μl RPE buffer 
and centrifuged at 8,000 rpm for 2 min. After removing the flow-through, the samples were 
centrifuged for another 1 minute at maximum speed to remove any residual flow-through. 
Finally, the RNeasy spin column was placed in a new 1.5 ml collection tube, 30 μl of RNase 
free water was added and centrifuged for 15 s at 8000 rpm in two consecutive steps to elute the 
RNA. The concentration of the RNA yield was measured by NanoDrop ND-1000 
Spectrophotometer based on the absorbance at 260 nm. 
2.3.2 cDNA synthesis 
The cDNA synthesis to be used for real-time quantification was performed by using High 
Capacity cDNA Reverse Transcription Kit in a 20 μl reaction. Firstly, 1000 ng RNA sample 
was prepared in 10μl (100 ng/μl) volume by diluting with milliQ water according to each 
sample concentration. Secondly, a master mix was prepared in 10 μl volume by combining 2 
μl 10X RT buffer, 2 μl 10X RT random primers, 0.8 μl 25X dNTP Mix 100mM, 1 μl reverse 
transcriptase (all from applied biosystem, Cat No. 4368813) and 4.2 μl miliQ water. The 10 μl 
RNA sample and the 10 μl master mix were mixed well together to make 20 μl reaction volume 
(give rise to final concentration 50 ng RNA/μl) and the mixture was then transferred to a 
thermal cycler (MJ mini, Bio-Rad) and the loading program was set for 10 min at 25°C , 120 
min at 37°C , 5min at 87°C and 4°C for holding. The cDNAs were ready to be used in qPCR 
and could be stored in -20°C. 
2.3.3 Quantitative PCR (qPCR) 
Probe based quantitative PCR (qPCR) was used in this study to detect mRNA expression of 
PDK isoforms in the PDK1-4 overexpressed cells. It is the most sensitive technique for 
detecting and quantifying even low-abundance mRNA in the target sample. This method 
measures florescence intensity emitted by the probe at each cycle of the reaction and the 
intensity gradually increases as the reaction advances. The software associated with the qPCR 
machine determines a threshold level to reduce background intensity. The point at which the 
reaction curve reaches the threshold level produces a Ct (cycle threshold) value which represent 
the number of cycles required for the fluorescent signal to cross the threshold [103]. 
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A 10-fold (for PDK probes) and 100-fold (for reference probe) dilution series were made from 
the synthesized cDNA samples to run the qPCR reaction. To avoid error in mRNA 
quantification, eukaryotic 18s rRNA (4352930E, FAM™ Dye⁄MGB Probe, Thermo Fisher 
Scientific) was used as endogenous control in each of the samples. A 36 μl of reaction stock (+ 
1.2% safety) was made containing 18 μl LightCycler 480 Probes reaction mix (04887301001, 
Roche, Basel, Germany), 1.8 μl TaqMan PDK1-4 probes (Hs 00176853_m1, Hs 
00176865_m1, Hs 00178440_m1, Hs 01037712_m1, Applied biosystem), 1.8 μl reference 
probe (18s rRNA), 9 μl of RNase-free water and 5.4 μl of cDNA for each sample per well of 
96-well plate. We wanted to look at the expression of other PDK mRNAs in each of the PDK 
overexpressing cells against each PDK probe. For this, a bulk quantity (183.6 μl, 6x sum of the 
aforementioned amounts) was first made in four 1.5 ml microtubes without the cDNAs. To 
achieve better control, equal volume of a reaction mix containing only 18s probe was prepared 
(PDK probe exclusion adjusted to water) in a separate tube. 30.6 μl of each reaction mix was 
manually pipetted in first six wells of a 96-well plate. Then 5.4 μl of 100-fold diluted cDNA 
samples were added in the wells containing 18s rRNA probe mix and 10-fold diluted cDNAs 
were added in the wells with 18s+PDK probe mix. Three technical replicates each of 10 μl 
were then manually transferred from the 96 well plate to a LightCycler® 480 Multiwell Plate 
384 (Roche, Basel, Germany). 
The 384 well plate was loaded to the LightCycler 480 system (Roche, Basel, Germany) to 
perform the qPCR following the program setting as listed in Table 2.1. 
 
Table 2.1 Program setting of Light Cycle 480 system for qPCR 
PCR Stages Temperature (ºC)  Time (mm:ss)  
Pre-incubation  95ºC 10:00 mins 
Amplification (45 cycles)  
Denaturation 95ºC  00:10 secs 
Primer annealing  60ºC  00:30 secs 
Extension 72ºC  00:01 secs 
Cooling  40ºC 00:30 secs 
 
After completion of the cycles, Ct values generated curves representing the number of the 
cycles needed to detect the florescence from each sample by LightCycler® 480 system. The 
higher the Ct value, represents lower gene expression and vice versa [104]. The data was 
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collected from the LightCycler® 480 system, which could then be used to perform comparative 
analysis between expressed genes and housekeeping genes, as expressed as delta Ct value. The 
relative expression fold change of the expressed genes could be determined from the ct values. 
The analysis of Ct value uses the following equation [105]: 
Ct = PCR cycle 
∆Ct = Ct (gene test) – Ct (endogenous control)  
∆∆Ct = treated (Ct (gene test) – Ct (endogenous control)) – untreated (Ct (gene test) – Ct 
(endogenous control)) 
Relative quantification (RQ) = 2-∆∆Ct  
Relative quantification is the fold change of the treated samples compared to the untreated. The 
RQ values for PDK gene expression were generated in Microsoft excel 2016 which were 
graphically presented and analyzed using Graphpad Prism 7. 
2.4 Cell lysis and isolation of proteins  
Cell pellets for protein isolation were prepared beforehand (see section 2.2.4). They were taken 
out from the -80 freezer and thawed on ice. The cells were lysed directly in the Eppendorf tubes 
by 300 µl of 1X RIPA lysis buffer supplemented with 1% Sodium Orthovanadate (SO) and 1% 
Phenylmethylsulfonyl fluoride (PMSF) obtained from Santa Cruz biotechnology, Cat. No. sc-
24948, along with 1% phosphatase cocktail inhibitor (Sigma-Aldrich) and 1% protease cocktail 
inhibitor (PIC, Complete ULTRA Tablets, Mini, EDTA-free from Roche Diagnostics, Cat. No. 
05892791001). The tubes were left on ice for 20 minutes after adding lysis buffer, then 
centrifuged at 4°C at 14000 rpm for 7 min. The DNA and cellular debris were pelleted, and the 
clear supernatant contained the total cell lysate. The supernatant was transferred to new 
microcentrifuge tubes which could be used immediately or stored at -80°C for later use.  
2.4.1 Determination of protein concentration 
Bicinchronic Acid (BCA) assay was performed to quantify total protein concentration in the 
lysate by using Pierce™ BCA Protein Assay Kit from ThermoFisher Scientific (#23225). The 
standard curve was generated from the serial dilution of the Bovine serum albumin (BSA) 
standard solution that comes with the kit, making eight ranging concentrations from 0 to 2000 
µg/ml. 25μl of these nine samples were carefully aliquoted into a 96 well plate (Nunc™ 
MicroWell™ 96-Well Microplates) in duplicates. Similarly, 25μl of the lysed protein samples 
were aliquoted in the same plate in duplicates. The working solution of BCA was prepared by 
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mixing BCA reagent A and BCA reagent B in 50:1 ratio, and 200 μl of this working reagent 
was loaded into each well. They were mixed and incubated for 30 minutes at 37°C under light 
protection.  The plate was then transferred to a plate reader (Thermo Scientific™ Multiskan™ 
FC Microplate Photometer) and the absorbance of the samples were measured at 562 nm. The 
absorbance values were inserted into an Excel sheet to obtain the standard curve that were used 
to determine the protein concentrations and to calculate the amount of proteins to be loaded 
into the SDS-PAGE. 
2.4.2 Sodium Dodecyl Sulfate Poly Acrylamide Gel Electrophoresis (SDS-PAGE) and 
Western blot buffers 
SDS-PAGE and Western blot of proteins require a few buffers to be repeatedly used throughout 
the process. Table 2.2 lists all the buffers that were used before proceeding to experimental 
details.  
 
Table 2.2 List of buffers with composition and suppliers’ information used for analysis 
of PDK proteins 
Buffers Stock solution Preparation of working 
solution (1x/1L) 
Suppliers 
Loading buffer XT Sample Buffer 
 




10x Tris/Glycine/SDS 100 ml 10x stock + 900 
Milli -Q H2O gives 25 mM 
Tris, 192 mM Glycine & 





5x Tris/Glycine 200 ml 10x stock+ 200 ml 
100% ethanol+ 600 ml 
Milli-Q H2O gives 25 mM 







Buffer in TBS 
containing 0.1% sodium 
azide 





Pierce™ 20X TBS 50 ml 20x stock+ 950 ml 
Milli-Q H2O+ 1 ml Twin-
20 gives 25 mM Tris, 






2.4.3 SDS-PAGE  
After the concentrations of the protein samples were determined, the volume of the samples 
was calculated based on the amount of the proteins (10 µg/well) we intended to have in each 
well. In order to obtain the 15 µl loading volume, the samples were mixed with equal volume 
of XT sample buffer and diluted with Milli-Q water so that the protein concentration is equal 
for every sample. The samples were then heated for 5 min at 95°C to denature the proteins. 
Two 4-20% gradient Mini-PROTEAN® TGX™ Protein Gels, 15-well #4561096 supplied by 
Bio-Rad were used for separating the proteins and were placed in the electrophoresis apparatus 
(Bio-Rad Mini Protean 3 cell system) filled with 1x running buffer. Precision Plus Protein™ 
Dual Color Standards (10–250 kD, #1610374, Bio-Rad) was used as molecular marker. 15 µl 
of the marker as well as the samples were loaded in pre-determined wells. The loading was 
done in a way such that each gel can produce two blots (after cutting in the middle), each 
containing all five protein samples (PDK1-4 + WT control) along with the marker. The 
electrophoresis first started at 90V for 15 min and then the voltage increased to 110V, the gels 
were run for next 1h until the blue tracking dyes end their journey out of the gels. 
2.4.4 Transfer of proteins by blotting 
The Polyvinylidene fluoride (PVDF) membrane (Trans-Blot® Turbo™ Mini-size LF PVDF) 
was used for blotting and was first activated in methanol for 30 sec, followed by washing with 
distilled water and then in 1x Transfer buffer. The transfer stacks were also prepared by soaking 
in transfer buffer and the gels were taken out of the gel cassettes. The transfer sandwich was 
made on the transfer cassette in the order: transfer stack in the bottom, the activated PVDF 
membrane, the gel, and another transfer stack on the top. Two transfer cassettes containing two 
sandwiches were then placed inside the Trans-Blot® Turbo™ Transfer System (Bio-Rad) for 
rapid transferring of the proteins within 7 min. After transfer was complete, the two membranes 
were rinsed with water and cut in the middle making four separate blots in order to be treated 
with four different antibodies. 
2.4.5 Total protein staining and blocking 
Total protein staining of the blots was done with REVERT™ Total Protein Stain kit (LI-COR 
Biosciences, # P/N: 926-11010) with methanol added. Following the manufacturer’s protocol, 
the membranes were incubated with 5 ml REVERT Total Protein Stain solution for 5 min in 
gentle shaking. The staining solution was decanted thoroughly, and the membranes were 
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washed with REVERT wash solution twice for 30 secs. The membranes were then imaged at 
680 nm IRshort channel (the staining solution has an excitation and emission spectrum near 
700 nm) in Amersham Typhoon Gel and Blot Imaging Systems (GE healthcare). After imaging, 
the membranes were incubated in REVERT reversal solution for ~5 min, in gentle shaking 
until the stain was no longer visible. The membranes were rinsed briefly with water and 
proceeded immediately to blocking. For blocking, the membranes were placed in small western 
blot incubation boxes containing 5 ml of Odyssey Blocking Buffer (TBS) and continued to 
block with gentle shaking in room temperature for more than one hour. Blocking is done to 
prevent nonspecific binding of the detection antibodies in the membrane. 
2.4.6 Preparation of the antibodies and immunoblotting 
The primary and secondary antibodies that were used for immunoblotting were prepared 
according to the recipes listed in the Table 2.3 (see following page). 
The four membranes were incubated with anti-PDK1, anti-PDK2, anti-PDK3, and anti-PDK4 
primary antibodies overnight at 4°C on a roller mixer (Stuart). The next day, the primary 
antibody solutions were poured off (re-usable) and washed three times for 5 min with 1X  
TBS-T buffer. The anti-PDK1, anti-PDK2, and anti-PDK3 treated membranes were again 
incubated with diluted donkey anti-rabbit IgG secondary antibody, whereas anti-PDK4 treated 
membrane was incubated with goat anti-mouse IgG secondary antibody for around 2 h under 
light protection and gentle shaking. The membranes were again rinsed with 1X TBS-T for 5 
min under vigorous shaking. The washing was repeated three additional times, the last step was 
only with 1X TBS to remove residual Twin-20. The membranes were then scanned at 800 nm 
IRlong channel in Amersham Typhoon Gel and Blot Imaging Systems (GE healthcare) to 
produce images of the desired protein bands. Amersham™ Imager 600 software was used to 
view and analyze the blot images. 
Mouse anti-α-Tubulin and mouse anti-GAPDH were used as loading controls. The incubation 
procedure was same as PDK primary antibodies as described above, followed by incubation 








Table 2.3 List of antibodies used in western blotting 
Antibodies Dilution & preparation in 
Odyssey Blocking Buffer (TBS) 
Supplier 
Anti-PDK1 antibody, 49 KDa, 
Rabbit monoclonal 
1:1000, 5 ml blocking buffer+ 5 µl 
antibody+ 10 µl Twin-20 (0.2%) 
Abcam 
#ab207450 
Anti-PDK2 antibody, 46 KDa 
Rabbit polyclonal IgG 
1:1000, 5 ml blocking buffer+ 5 µl 
antibody+ 10 µl Twin-20 (0.2%) 
Invitrogen 
# PA5-35376 
Anti-PDK3 antibody, 47 KDa 
Rabbit polyclonal IgG 
1:1000, 5 ml blocking buffer+ 5 µl 
antibody+ 10 µl Twin-20 (0.2%) 
Invitrogen 
# PA5-76332 
Anti-PDK4 antibody, 46 KDa 
Mouse monoclonal 
1:500, 5 ml blocking buffer+ 10µl 
antibody+ 10 µl Twin-20 (0.2%) 
Abcam  
#ab110336 
IRDye® 800CW Goat anti-
Mouse IgG Secondary 
Antibody 
1:20000, 5 ml blocking buffer+ 




IRDye® 800CW Donkey anti-
Rabbit IgG Secondary 
Antibody 
1:20000, 5 ml blocking buffer+ 




Anti-α-Tubulin antibody, 50 
KDa, Mouse monoclonal 
1:1000, 5 ml blocking buffer+ 5 µl 
antibody+ 10 µl Twin-20 (0.2%) 
Abcam  
#ab7291 
Anti-GAPDH antibody, 35.8 
KDa, Mouse monoclonal 
1:1000, 5 ml blocking buffer+ 5 µl 




2.4.7 Quantification of blots 
For quantification, ImageJ analysis software was used to calculate the relative amount of 
proteins in the samples compared to the loading control, α-Tubulin or GAPDH. The 
backgrounds were rejected, and the area intensity values of each protein band (both α-
Tubulin/GAPDH and PDKs) were exported into an excel sheet. First, a normalization factor 
was calculated for the α-Tubulin /GAPDH by dividing the values of each protein sample with 
the WT control value. Second, these NF values were multiplied to the corresponding PDK 





2.5 Cell proliferation assays 
2.5.1 xCELLigence system 
A label-free RTCA (real-time cell analysis) platform called xCELLigence system from ACEA 
Biosciences was used in this study as one of the methods for assessing cell proliferation. The 
system utilizes an electronic readout called impedance analysis for real time monitoring of 
adherent cell proliferation and viability on tissue culture microplates. The RTCA instrument is 
composed of a RTCA impedance analyzer, electronic microwell plates and a RTCA station 
placed inside an incubator which is connected to a computer with RTCA software. For cellular 
proliferation assay, 16-well E-plate was used and the bottom of each well is 80% covered with 
gold-electrodes. As the cells proliferate, the more they attach and cover the electrodes, thus 
giving higher impedance. The impedance measurement is displayed as cell index (CI) 
(generated by RTCA software) value and provides quantitative information about the 
biological status of the cells, including cell number, viability, and morphology [106]. 
 
Proliferation study of PDK overexpressing cells started with one 1x T75 flask for each 
anfollowed normal propagation procedure as described in section 2.1.3. For each of the cell 
lines, 40,000 cells/ml were prepared in high glucose cDMEM (the cell number was previously 
been optimized in the laboratory). 100 μl of cDMEM was added in each well of an E-Plate 
VIEW 16 (ROCHE, Acea Biosciences Inc. San Diego, CA92121) and the program schedule 
was set for 100 h prior to measuring the background index of the plate inside the RTCA station. 
Thereafter, 100 μl of each cell suspension, that gives 4000 cells per well were added in the 
wells as triplicates and incubated for 30 min in room temperature. After incubation, the plate 
was inserted in the machine, connection was checked in the message and the experiment 
started. Therefore, the cells were maintained at optimal culture conditions (5% CO2, 37
0 C) 
throughout the experiment up to 100 h. 
The growth curves of the proliferating cells could be seen real-time in the monitor during the 
experiment. The measurements were paused every 24 h, the plate was taken out and 10 μl of 
media was collected from each of the wells to measure glucose consumption and lactate 




2.5.2 Live-cell proliferation assay on IncuCyte platform 
The IncuCyte™ ZOOM (Essen Bioscience) is a platform for continuous monitoring of cells 
that allows acquiring, analyzing and quantifying live cell images by using time-lapse imaging 
method. Viable cells are measured inside an incubator (37°C with 5% CO2) in a physiologically 
relevant condition without being perturbed by the detection method. The system can house 6 
micro-titer plates at a time and scan the plates on a customizable duty-cycle. There are three 
objectives with magnifications of 4x, 10x and 20x. To determine glucose-dependent 
proliferation of PDK-overexpressing cells 10x objective was used, as a general protocol. 
The 231 WT and 231 PDK1-4 cells were seeded in a 96-well plate (Nunc, Cat. #167008), with 
seeding density 3000 cells/well in 100 µl of 1 mM, 5 mM, and 25 mM glucose medium. The 
plate was left to equilibrate at room temperature for 45 min. By this time, 1M of DCA working 
solution was made from 98% Sodium dichloroacetate (DCA, Lot# STBH0169, Sigma-Aldrich) 
in MQ H2O. 5 µl DCA was added to the selected replicates of 25 mM glucose groups, leading 
to final DCA concentration 50 mM. The plate was left overnight at 37 °C, 5% CO2 incubation. 
The next morning, the scanning schedule was created in the incuCyte ZOOM® Software such 
that images were captured under 10x magnification every 2 h for a total of 72 h. The cell plate 
was placed into the IncuCyte system and first allowed to warm to 37°C for 30 min prior to 
scanning. The algorithm in the ZOOM software generated growth curves from data points of 
every 2 h interval imaging acquired throughout the experiment. The data was exported in excel 
sheet and analyzed via Graphpad prism 7. 
2.5.3 Resazurin Assay 
To determine the viability of the PDK-overexpressing cells, the plates that came out from 
IncuCyte experiment were again undergone resazurin conversion assay. Resazurin (7-
Hydroxy-3H-phenoxazin-3-one 10-oxide), the active ingredient of alamarBlue assay is a blue-
colored non-fluorescent dye, that has been widely used as an indicator of cell viability in many 
cell proliferation and cytotoxicity assays [107]. It is non-toxic and can enter living cells, so 
when resazurin is present, viable cells reduce resazurin into a pink-colored fluorescent 
compound, resorufin. In a population of cells, this conversion of resazurin to resorufin is 
proportional to the number of viable, metabolically active cells which can be a way of assessing 
proliferation [108]. 
While running the IncuCyte experiment, the cells were continuously being incubated for 3 
days, and soon after the IncuCyte was done, the resazurin assay started. The working 
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concentration of resazurin was made as 1:20 dilution (1X) in PBS from 2.5 mg/ml stock 
(Sigma, cat. no. R7017) and 20 μl 1X resazurin was added directly to each well and mixed by 
gentle shaking. The plate was light protected by wrapping in aluminum foil and placed in an 
incubator at 37°C in 5% CO2. Following incubation for 3h, the fluorescence for metabolic 
reduction of resazurin to resorufin was measured by Tecan’s Spark® multimode microplate 
reader platform at 550/600 nm (excitation/emission). 
2.6 Monitoring mitochondrial respiration and glycolysis by Seahorse extracellular flux 
(XF) analyzer 
The Seahorse extracellular flux (XF) Analyzer serves a powerful technique for measuring 
mitochondrial respiration and glycolysis simultaneously in the same cell. The technology uses 
fluorescent probes coated in a sensor cartridge sensitive to oxygen and protons to measure 
oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) respectively, in 
the medium directly above adherent cells. ECAR is primarily the measurement of acidification 
of the surrounding media caused by lactate production from the conversion of pyruvate [29, 
109].  
Bioenergetic parameters of metabolic function can be revealed from measurement of OCR and 
ECAR values (Figure 2.1). To assess respiratory parameters, the first measurement is basal 
respiration which represents oxygen consumption needed to meet cellular energy demand 
under baseline conditions. The second measurement is ATP -linked respiration upon injection 
with ATP synthase inhibitor, oligomycin that causes a decrease in the OCR. The difference 
between basal and ATP-driven respiration is referred as leak respiration which represents any 
oxygen consumption that was not coupled ATP synthesis. The next parameter is to obtain 
maximum respiratory capacity after addition of a mitochondrial uncoupler (e.g CCCP, FCCP). 
This creates a cellular energy demand that stimulates the respiratory chain to act at its 
maximum capacity and as ETC increases, oxygen consumption goes up. Finally, non-
mitochondrial respiration is measured after complete inhibition of ETC upon sequential 
addition of respiratory inhibitors (e.g rotenone and antimycin A) (Figure 2.1A) [73]. 
Similarly, to assess glycolytic key parameters, the first measurement is glucose-induced 
response in glycolysis under basal conditions. The second measurement is oligomycin-
mediated inhibition of mitochondrial ATP production that allow the cells to depend more on 
glycolysis, thereby revealing maximum glycolytic capacity. The final step is inhibition of 
glycolysis through the addition of a glucose analogue, 2-deoxy-glucose (2-DG) with a 
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subsequent reduction in ECAR and the remaining ECAR is referred as non-glycolytic 
acidification (Figure 2.1B) [110]. 
 
 
Figure 2.1 The fundamental parameters of mitochondrial and glycolytic functions.  
(A) Key parameters of mitochondrial bioenergetics measured based on OCR values. The 
compounds, oligomycin, FCCP, and a mix of rotenone and antimycin A, are sequentially 
injected to measure basal respiration, ATP-linked respiration, maximal respiration, and non-
mitochondrial respiration, respectively. Proton leak and spare respiratory capacity can be 
calculated from these parameters in terms of basal respiration (B) key parameters of glycolytic 
function measured based on ECAR. Sequential injections of glucose, oligomycin and 2-DG 
measure glycolysis, glycolytic capacity, and non-glycolytic acidification respectively from 
which glycolytic reserve can be calculated. Adapted from [87, 110]. 
 
2.6.1 Seeding of cells and preparing the sensor cartridge 
The seahorse experiments for 231 PDK1-4 cells were performed according to standard 
protocols. The cell numbers and compound concentrations has previously been optimized in 
Prof Tronstad’s laboratory. But the optimal CCCP concentration for newly transduced 231 
PDK1-4 was not determined. As a result, 231 WT and 231 PDK4 cells were seeded 30000 
cells/80µl/well in a 96-well assay plate (XFe96 Cell Culture Microplates, #101085-004) in two 
different glucose concentration (1 mM and 25 mM) to perform a CCCP titration assay. For the 
assessment of general metabolic function, all five cells were seeded in two assay plates with 
the same seeding density (30000 cells/well) under pre-treatment with three concentrations of 
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glucose (1 mM, 5 mM, and 25 mM). They were allowed to attach overnight at 37 °C with 5 % 
CO2 in air. 
To achieve consistent result, the sensor cartridges must be hydrated overnight. 200 µl of 
Seahorse XF Calibrant Solution was added to each well of a XFe96 utility plate (FluxPaks cat 
# 102416±100). The sensor cartridge was submerged in the calibrant solution and left overnight 
in a CO2 free incubator (PrepStation, Agilent) at 37 °C to hydrate. 
2.6.2 Mitochondrial and glycolysis stress tests 
For metabolic study of PDK-overexpressing cells, the Seahorse XFe96 Analyzer (Agilent, 
Santa Clara, CA, US) was used to perform two standard assays, Agilent Seahorse XF Cell Mito 
Stress test and Glycolysis Stress test. These stress tests use sequential injection of certain 
compounds that have been mentioned in section 2.8.1. After overnight incubation in different 
glucose treatments, the growth media were replaced with unbuffered DMEM assay media 
(phenol red-free, D5030) supplemented with 10 mM D-glucose, 2 mM sodium pyruvate and 2 
mM L-glutamine for the Mito stress test with the pH adjusted to 7.4. For glycolysis stress assay, 
media was replaced with glucose-free assay media supplemented only with 2mM glutamine at 
pH 7.4 The cell microplates with assay media were then incubated for at least 1 h in the 
PrepStation. 
The inhibitors and modulators of the stress tests were adjusted to proper concentration in 3ml 
of respective unbuffered assay media. The final concentrations of the modulators in the well 
were 3 µM oligomycin, 1 µM CCCP, 1 µM rotenone and 1 µM antimycin A for Mito stress 
test and 10 mM glucose, 3 µM oligomycin and 100 mM 2-deoxyglucose were the final 
concentrations for glycolysis stress test (all obtained from Sigma-Aldrich). For CCCP titration 
assay, the CCCP concentrations ranged between 0.25 to 2 µM along with the 3 µM oligomycin 
,1 µM rotenone and 1 µM antimycin A. 25 µl of each of these additives were pipetted into the 
injection ports A, B, C, D of the sensor cartridge in the order they are listed above so that 
seahorse instrument could sequentially inject the chemical modulators onto the cells to obtain 
metabolic flux profiles. The sensor cartridge with the utility plate was first inserted into the 
machine for calibration and then the utility plate was replaced with the cell culture plate. The 
protocol for the measurements is 3 cycles of 3 min measurement and 3 min mixing, between 
each injection of modulators.  
At the end of the assay, media in the wells were removed and the plates were kept in -80°C 
freezer overnight to lyse the cells. Total protein content was measured by Pierce® BCA Protein 
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assay (described in section 2.4.1.) and the OCR and ECAR values obtained were normalized 
to protein (per μg) content. 
2.7 Substrate oxidation assay by 14CO2-trapping 
14CO2 capture is a standard technique for evaluation of cellular oxidation of substrates. A 
modification of the traditional method (cells or cell lysate in a sealed vial) involves using cell 
cultures and filter plates designed to be used in a multiplate scintillation spectrophotometer 
[111]. The method uses a standard 96-well tissue culture plate and a filter plate having the filter 
plate (activated with NaOH) inverted on top of the cell plate, sealed with a silicon-gasket in 
the middle to obtain a gas-tight compartment (See Figure 2.2) [112]. 
 
 
Figure 2.2 The principles of the 14CO2 trapping system. The released CO2 from the 
oxidation of 14C-labeled substrate will be trapped by the alkaline suspension in the filter plate 
[112]. 
 
2.7.1 Preparation of samples and media  
Substrate oxidation rate of PDK overexpressed cells were assessed by trapping released 14CO2 
as described by Wensaas et al. after being treated with two different radiolabeled carbon 
substrates (14C) [112]. Cells were seeded as 45 000 cells/well in two 96-well CellBind® 
microplates in pre-treatment with different concentrations of glucose (1mM and 25 mM or 
1mM, 5 mM, and 25 mM, depending on the experiment) and incubated overnight (37°C in 5% 
CO2) for proper attachment. The radiolabeled substrates used were [1-
14C]pyruvic acid (0.25 
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µCi/ml) and [1-14C]palmitic acid (1 µCi/ml), supplied by PerkinElmer (Waltham, MA, US). 
The assay media with these substrates were prepared in 5 ml of Dulbecco’s Phosphate Buffered 
Saline (DPBS) (with MgCl2 and CaCl2, D8662, Sigma-Aldrich) supplemented with 10 mM 
HEPES, 0.5 mM glucose and 10 µM BSA (i.e. 7.06 µM for palmitic acid). Additionally, 1 mM 
L-carnitine was added in the assay medium for palmitic acid (PA) oxidation. To obtain final 
concentrations of 200 µM of sodium pyruvate and 100 µM of BSA-conjugated PA, calculated 
amount of respective non-radiolabeled substrate was added. The reduced amount of BSA in 
the assay medium for PA was because the cold fatty acid (non-radiolabeled) is conjugated to 
BSA (40µM BSA in 100µM cold PA). For uncoupled substrate oxidation, two optimized 
concentrations for CCCP, 10 µM for pyruvate and 30 µM for PA oxidation were prepared in 
DPBS. The optimal concentration of CCCP was made higher for PA than pyruvate, due to 
increased amount of BSA in PA medium, CCCP will bind to BSA. 
2.7.2 The 14CO2 trapping procedure 
At first, the cells were monitored under a light microscope and the media was removed and 
saved in a new 96-well plate to be used for measuring glucose and lactate concentration. The 
two plates were labeled for two substrates, and 50 µl of the corresponding radioactive assay 
medium was added to the cells. 5 µl of 10 µM and 30 µM CCCP stock was added to the selected 
wells of pyruvate and PA plate, leading to final concentration 1 µM and 3 µM respectively. 
UK-5099 (5 µM, inhibits the transport of pyruvate into the mitochondria, by inhibiting the 
mitochondrial pyruvate carrier (MPC)) and Etomoxir (40 µM, inhibitor of fatty acid oxidation, 
by irreversible inhibition of carnitine palmitoyltransferase-1, CPT-1) were also added to some 
wells to monitor non-mitochondrial CO2 production. In another experiment, after adding 
radioactive assay media, the cells were treated with a range of DCA concentrations (20 µM, 30 
µM, 40 µM, 50 µM) in order to investigate DCA-mediated influence in substrate oxidation. A 
96-well filter plate (UniFilter: GF/B) was prepared beforehand by immersing with 25 µl of 1M 
NaOH. After adding all treatments, the cell plate was clamped together with the filter plate in 
a sandwich like structure in the order: cell plate/silicon gasket/inversed filter plate (as described 
by [112], see Figure 2.2). The trapping apparatus was placed in an incubator (37°C) and was 
allowed to trap CO2 for 4 h. The 
14CO2 captured in the filters could be monitored by addition 
of scintillation liquid (30 µl, MicroScint PS PerkinElmer) to the filters, followed by sealing 
with a TopSealA (PerkinElmer). Radioactivity was counted in a microplate scintillation 
counter (MicroBeta2 Microplate Counter, PerkinElmer). The cell plates containing the 
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radioactive media and treatments was used for protein measurement and cell-associated 
radioactivity. 
2.7.3 Measurement of protein and cell associated radioactivity 
The media was removed, washed twice with PBS, and 0.1M NaOH was added to lyse the cells.  
50 µl of lysed cells were taken in a Nunc™ MicroWell™ 96-Well Microplate for measuring 
protein concentration using Pierce® BCA Protein Assay Kit as described in section 2.4.1. 
Another 50 µl of lysed cells were transferred to an Isoplate-96 Microplate (PerkinElmer) and 
100µl of scintillation liquid (UltimaGold XR) was added to each well and sealed with a 
TopSealA. The plate was left to incubate for 2 h and the radioactivity was measured in the 
same MicroBeta scintillation counter. All the procedures and instrument handling were done 
in a specialized room for isotope handling and with appropriate personnel protection. 
2.8 Media lactate and glucose measurements 
Lactate that is produced as a metabolic by-product of glucose metabolism has also effects in 
cell growth and metabolic activity (Ozturk SS). Biosen C-Line GP+ (EKF Diagnostics, Cardiff, 
UK) was used to measure glucose and lactate concentrations in the media that were collected 
during xCELLigence and 14CO2 trapping experiments. Biosen uses a special chip sensor 
technology for quick and efficient measurement of glucose and lactate within the measuring 
range 0.5–50 mmol/L and 0.5–40 mmol/L respectively. The sensor contains immobilized 
enzyme glucose oxidase / lactate oxidase which catalyzes the oxidation of β-D glucose / L-
lactate contained in the sample and the hydrogen peroxide (H2O2) produced is detected at the 
electrode.  
Before starting measurement, a solution of known concentration (EKF Multi-standard) was 
placed in the device to be automatically calibrated. Then 10 mM of pure glucose and lactate 
solutions were measured as control to check instrument accuracy. 4 µl of media was precisely 
taken in micro-tubes and mixed with 200 µl of hemolysis solution (1:50 dilution) by gentle 
pipetting. The samples were inserted into the analyzer where they were automatically taken up 
and moved to the sensor. The results were generated after 20-45 sec. 
2.9 Data analysis 
Data from all experiments were calculated and analyzed by Microsoft excel and Graphpad 
Prism 7 software and presented as either mean ± standard deviation (SD) or mean ± standard 
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mean error (SEM). Statistical analysis of data was performed by ordinary one or two-way 
ANOVA followed by Tukey’s multiple comparisons test in Graphpad. P<0.05 was considered 
as significant to indicate a statistical difference. The bands from western blot data was 
































3.1 mRNA expression analysis confirms PDK overexpression in MDA-MB-231 cells 
The stable transduction of PDK1-4 in MDA-MB-231 cells was done by Phoenix retroviral 
packaging system. To confirm successful overexpression in the stably transduced MDA-MB-
231 cells prior to experimental proceeding, the increased expression of PDK1-4 mRNAs was 
confirmed by qPCR analysis. Expression of each of the PDK1-4 mRNAs was significantly 
upregulated in the respective target sub-lines compared to WT cells (Figure 3.1). Figure 3.1A 
show expression levels immediately after the selection process, and Figure 3.1B after a second 
selection process 3 months later to ensure that the cells still had the inserted construct.  
The data from these two time points showed similar PDK1-4 mRNA expression profile. Both 
figures show elevated expression of each four PDK mRNAs in their host cells, though with 
some variation in magnitude. For instance, fold induction was highest in the PDK4 
overexpressing cells compared to the WT cells. Still, all PDKs were considered highly 
expressed based on their high fold change in the respective cells. The relative increase in 
PDK1-4 expression ranged between 60- to 2000-fold in the first quantification (Figure 3.1A), 
whereas it was some lower in the second as it ranged from 30- to 350-fold (Figure 3.1B).  
Decreased overexpression between the first and second measurement was particularly seen for 
the PDK1 and PDK4 mRNAs. Besides, the expression level of other non-overexpressed PDKs 
in each of the transduced cell lines as well as in WT was also measured, however, their 
expression was quite low and was not affected by the overexpression (data shown in 
supplementary Table 8.1).  The expression for WT is not presented in the graph since the mean 
for WT expression was 1 by default, as fold-change for PDK mRNAs was calculated relative 





Figure 3.1 The upregulation of PDK1-4 mRNAs  confirmed by quantitative real-time 
PCR in the cell lines overexpressing the respective target mRNA (A) The increased 
expression level of PDK1-4 mRNAs detected after the first selection process. (B) The increased 
mRNA expression was further confirmed after 3 months upon reselection of the cells. For 
quantification, the amount of PDK1-4 mRNA expression was normalized to 18S rRNA mRNA 
expression. The X-axis data shows the corresponding mRNA measured in each PDK-
overexpressing cell and Y-axis data shows mRNA expression fold change relative to the WT 
control (ddCT method). Values are presented as mean ± SD and statistical comparisons was 
performed by one-way ANOVA. The asterisks indicate significant differences from the control 
group considering *P < 0.05; **P < 0.01; ***P < 0.001 and ****P < 0.0001.  
 
3.2 PDK overexpression leads to increased protein expression 
To further confirm PDK1-4 overexpression at protein level, western blot analysis was 
performed and the results are displayed in Figure 3.2. The level of overexpression was 
evaluated relative to the amounts of endogenous PDK isoforms measured in the WT cells. 
Detection with anti-PDK1 antibody showed an effective increase in PDK1 expression in the 
stably transduced 231 PDK1 cells (Figure 3.2A). There was low expression of PDK1 in the 
other transduced cell types, as well as in the parental WT cells. Similarly, high expression was 
observed for PDK2 protein in 231 PDK2 cell with no or low expression in other cells (Figure 
3.2B). Similar expression patterns were observed in the other blots for PDK3 and PDK4 
proteins (Figure 3.2C and Figure 3.2D). The PDK isoforms have molecular weight ranging 
between 46-49 KDa and all the bands were detected at ~46 KDa. Anti-GAPDH (and anti-α-
tubulin, data not shown) was used as a loading control and confirmed equal sample loading in 
all wells. The intensity of the respective bands on the western blot image was quantified, and 





Figure 3.2 Western blot analysis to verify successful stable overexpression of PDK1-4 
isoforms in terms of protein expression. A-D Representative blots showing increased protein 
expression of PDK1, PDK2, PDK3, and PDK4 against their specific antibodies in the 
respective PDK1-4 overexpressed cell lines, all were detected approximately at 46 KDa. Other 
PDKs show downregulation or poor expression including in the WT. E-H Quantification of 
relative PDK expression in each sample. X-axis represents the total protein samples in 231 
PDK1-4 cells and Y-axis represents PDK1-4 protein expression levels that were normalized to 
GAPDH expression, each relative to the WT Control. Anti-GAPDH detects a band of 




3.3 Effect of PDK overexpression on the proliferation of 231 PDK1-4 cells 
3.3.1 Growth characteristics by impedance analysis indicates increased proliferation in 
PDK overexpressed cells 
To determine if overexpression of the PDK isoforms causes changes in cell proliferation, we 
performed impedance analysis-based proliferation study by using the xCELLigence system. 
The cells were continuously monitored for 96 h and the generated growth curves are presented 
in Figure 3.3. The cell index (CI) values were normalized 5 h after the experiment started (i.e. 
2h after cell seeding) in order to obtain the relative growth of the cell cultures, after proper cell 
attachment and spreading. The normalized CI values display distinct growth profile for each 
cell type. 231 PDK1, PDK3, and PDK4 cells showed significantly higher proliferation than the 
WT cells whereas PDK2 had the slowest proliferation. Despite differences in the proliferation 
rate, the CI values were gradually increasing for all of them over time. PDK1 and PDK4 
overexpressing cells were growing at a similar rate for the first 24 h, but a slightly lower 
proliferation rate was observed for the 231 PDK4 cells for the rest of the experiment (see Figure 
3.3A).  
Based on the overall monitoring, we statistically compared the CI levels of all five cell types 
at specific time points 24 h, 48 h, 72 h, and 96 h (see Figure 3.3B). The relative differences 
between the cell lines at individual time points were almost the same, showing increased 
proliferation in the cells overexpressing PDK1, 3 and 4 compared to the parental WT cells. The 
differences in CI among the cell types, including the parental cells, were significant as 
calculated by two-way ANOVA. Of these cell types, the PDK1 cells displayed the highest 




Figure 3.3 Dynamic monitoring of proliferation in the PDK1-4 overexpressed cell lines 
using the xCELLigence impedance system. (A) Growth curves of 231 WT, PDK1, PDK2, 
PDK3, and PDK4 cells were recorded over a time period of 96 h in 16-well E-plates with a 
seeding density 4,000 cells/well. The vertical axis represents the cell index (CI) values that are 
normalized to first 5 h. The small breaks in the growth curves were due to experimental pause 
in those time points to collect media from the wells.  (B) The curves are plotted into standard 
bar graphs to compare CI values between the cell types at 24 h, 48 h, 72 h, and 96 h. The data 
are presented as the mean of three replicates ± SD. #P < 0.0001 was obtained by two-way 
ANOVA for each group relative to the WT control. 
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3.3.2 Determining glucose and lactate concentrations in culture medium 
In the xCELLigence experiment described above, we measured glucose and lactate 
concentrations in the culture medium at different time points. The process of medium collection 
caused small breaks in the CI data curve, as seen in Figure 3.3A (experimental pause). Figure 
3.4 displays the medium level of glucose and lactate after 24 h, 48 h, 72 h, and 96 h. Initially, 
the cells had 25 mM glucose in their media and the remaining glucose after 4 days of 
proliferation (96h) was around 18-20 mmol/L (Figure 3.4A). The level of glucose did not seem 
to be very different throughout their proliferation time. Further, the 231 WT and 231 PDK1 did 
not produce lactate until first 24 hours, later they produced up to 4 mmol/L. 231 PDK2 and 231 
PDK3 had similar lactate accumulation in the media between 24 h and 48 h, then 231 PDK3 
produced more lactate than 231 PDK2 for rest of the period. 231 PDK4 cells produced lactate 
at the highest rate from 24 h to 96 h, with an amount up to 5mmol/L (Figure 3.4B). The control 
media did not have any lactate present. The initial medium glucose concentration was measured 
to be 18-20 mmol/L, some lower than the estimated concentration, and was not found to change 
significantly in any of the cultures throughout the experiment. 
 
 
Figure 3.4 Measurement of glucose and lactate present in the cell culture media. The 
measurements were done during the proliferation study in xCELLigence. (A) Estimation of 
glucose concentration present in the media in the cultures of the 231 WT and PDK1-4 cells 
after 24 h, 48 h, 72 h, and 96 h (B) Estimation of extracellular lactate concentration in the 
culture media of 231 WT and PDK1-4 cells at the same time points. The amount of glucose 






3.3.3 Effect of glucose deprivation on the proliferation of PDK1-4 overexpressing cells 
The effect of PDK overexpression on cell growth was evaluated by cell culture imaging in 
IncuCyte® Live Cell Analysis system (IncuCyte) to investigate confluence-dependent 
proliferation. Unlike from the xCELLigence experiment, high (25 mM), moderate (5 mM), and 
low (1 mM) concentrations of glucose were used to determine the glucose dependency of the 
PDK overexpressing cells compared to WT cells.  
Figure 3.5 presents the morphology as well as proliferation curves of 231 WT and 231 PDK1-
4 cells recorded via IncuCyte for 72 h. The growth curves in  
Figure 3.5B-D are presented as fold change of % confluence values and are normalized to the 
time point of first image.  
In all three glucose conditions, the proliferation rate of PDK1-4 cells was almost same as the 
WT at least for first 20 h. Then a significant reduction in PDK1-4 cells’ proliferation was 
observed in 1 mM glucose compared to the other two glucose conditions, and it seems like they 
grew only for around 40h after which they growth curves started to decline. 231 PDK1 and 231 
PDK2 were found to be mostly affected by 1 mM glucose condition. Interestingly, the growth 
of the 231 PDK1-4cells were not affected by 5 mM glucose, whereas a slight increase in the 
proliferation of 231 PDK2, PDK3, and PDK4 was visible in 25 mM glucose.  
Figure 3.5E shows the approximate plateau datapoints that were picked for each cell type in 1 
mM glucose and plotted into standard bar graphs which shows subsequent reduction in 
proliferation in all 231 PDK cells in compared to the 231 WT cell.  
For 5 mM and 25 mM conditions, the end-point measurements of growth curves at 71.5h were 
plotted in standard bar graphs  
Figure 3.5F-G). The peak proliferation level for all the PDK overexpressing cell lines were 
slightly reduced in 1 mM glucose compared to 231 WT cells with statistical significance. This 
was not observed in higher glucose concentrations, suggesting that overexpression of either of 
the PDKs causes increased glucose dependency. There was a slight increase in the 231 PDK 







Figure 3.5 IncuCyte® cell proliferation assay of 231 WT & 231 PDK1-4 cells cultured in 
1 mM, 5 mM, and 25 mM glucose. The cells were seeded at 3000 cells/100 µl/well and 
confluence were recorded for 72 h at 10x objective. (A) Live cell morphology captured real-
time in 96-well format containing 25 mM glucose at 71.5 h (B-D) Growth curves showing 
proliferation profile of 231 WT and PDK1-4 cells throughout 72 h. (E) Proliferation of 231 
PDK1-4 cells at their plateau datapoints in 1 mM glucose. (F-G) Proliferation at 71.5 h in 5 
mM and 25 mM glucose conditions in each glucose condition. The vertical axis represents the 
fold change of % confluence and are normalized to the time point of first image.  The data 
presented here is representative of two independent experiments. *P < 0.05, **P < 0.01, 
***P < 0.001. 
 
We also performed a similar experiment where we evaluated viability/proliferation using the 
metabolic resazurin assay. The cells were first grown for 72 h in presence of 1 mM, 5 mM, or 
25 mM glucose, followed by 3 h incubation with resazurin. The fluorescence of resazurin 
conversion to resorufin by the proliferating cells were measured and the results are presented 
in Figure 3.6. The resazurin conversion experiment did not suggest that cell viability was 
reduced under the glucose-limited (1 mM) condition, as could be hypothesized from the 
previous proliferation data. In contrast, viability was increased in cultures with cells 
overexpressing PDK2, PDK3 or PDK4, compared to parental cells (Figure 3.6A). Further, the 
rate of resazurin conversion in the PDK-overexpressing cells were significantly higher than the 
WT parental cells in the 5 mM and 25 mM glucose condition particularly in the 231 PDK1, 
PDK2, and PDK3 cells (Figure 3.6B-C). The measurement of resazurin conversion represents 
a combined indicator of cell viability, proliferation, and metabolic rate.  
 
We also investigated if PDK-overexpression has any effect on proliferation under low-oxygen 
condition. We incubated the 231 PDK1-4 cells in the same glucose conditions for 72 h, but 
under physiological oxygen level (5% O2, 37
0C). However, the 231 PDK1-4 cells did not show 
any significant differences between normal (atmospheric) and physiological (normoxic) 





Figure 3.6 Determination of viability in 231 PDK1-4 cells by resazurin-based assay. The 
231 PDK1-4 cells were continuously grown for 72 h in 1 mM, 5 mM, and 25 mM glucose 
media with a seeding a density 3000 cells/100 µl. Following 3 h incubation with resazurin, the 
fluorescence of resazurin conversion to resorufin was measured at Ex560, Em600. Resazurin 
conversion rate by the PDK1-4 cells in (A) 1 mM (B) 5 mM, and (C) 25 mM glucose. The 
vertical axis represents the fluorescence of resorufin and the bars are presented as mean of 
replicates ± SD; Statistical tests were performed by one-way ANOVA, *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.001. 
 
3.3.4 Effect of DCA on proliferation of PDK1-4 cells 
Since we observed that PDK overexpression tends to have a positive effect on proliferation, at 
least when glucose supply is not limiting, we also tested the effects of PDK inhibition on 
proliferation with the use of DCA. DCA is a well-known inhibitor of all four PDK isoforms 
[114]. Effects of PDK inhibition on cell proliferation and viability were monitored by incuCyte 
imaging and resazurin conversion under the same conditions as in section 3.3.3. This was 
implemented as a part of the previously described experiments, and the effects of DCA were 
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therefore evaluated to the same untreated cell cultures as in Figure 3.5 and 3.6. 50 mM DCA 
was added in the selected replicates of 25 mM glucose condition, incubated for 3 days and the 
effect on PDK-overexpressing cells is showed in Figure 3.7.  
A massive reduction in proliferation in each of the PDK-overexpressing cell was observed in 
terms of resorufin fluorescence as well as percent confluence. Approximately 80-90% 
reduction in confluence (Figure 3.7A) and 60-65% reduction in resazurin fluorescence (Figure 
3.7B) was observed. 
 
 
Figure 3.7 Effect of DCA on the growth of 231 PDK1-4 cells assessed using the incuCyte 
instrument and the resazurin assay. 50 mM DCA in presence of 25 mM glucose was used 
for treating 3000 cells/100 µl, followed by 3 days incubation. (A) Reduction in % confluence 
due to DCA effect measured by the incuCyte instrument and (B) Reduction in resazurin 
fluorescence due to DCA effect measured by resazurin viability assay in compared to the 
untreated 25 mM glucose condition. The data are presented as the mean ± SD of 4 duplicated 
wells. Statistical analysis performed by one-way ANOVA, *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.001 
 
3.4 Rates of mitochondrial respiration and glycolysis in PDK1-4 overexpressing cells 
In order to investigate how energy metabolism is affected by PDK overexpression, we 
compared bioenergetic status of the PDK1-4 cells with the WT control based on measuring 
mitochondrial respiration and glycolysis. We had to first determine the optimal CCCP 
concentration and 1 µM CCCP was found to stimulate the maximum OCR in 231 WT and 
231 PDK4 cell (see supplementary Figure 8.2). Therefore, 1 µM was chosen as optimal 
CCCP concentration for further experiments.  
51 
 
3.4.1 Effect of PDK1-4 overexpression in mitochondrial respiration 
Mitochondrial respiratory analyses were performed by mitochondrial stress test in Agilent 
seahorse XFe96 analyzer, following overnight incubation with 1 mM, 5 mM, or 25 mM 
glucose. The overall respiratory rates of 231 PDK1-4 cells in compared to their WT parental 
cell are presented in Figure 3.8. 
Following the measurement of basal respiration, key parameters of mitochondrial function 
were assessed by sequential addition of pharmacological modulators (Figure 3.8A-C). The 
inhibitory effect of oligomycin, and the subsequent induction by addition of uncoupler CCCP, 
confirmed OXPHOS integrity under these conditions. For the 231 WT cells, basal respiration 
and maximum respiratory capacity tended to be higher in the cultures with 1mM glucose 
compared to 5 mM glucose (Figure 3.8 D-E). This potential adaptation to the limited glucose 
appeared to be absent in cells overexpressing PDK1, PDK3 or PDK4, as the respiratory rates 
were unchanged or higher in cells grown with 5 mM glucose, compared to 1 mM glucose. Due 
to these differences, the increase in respiratory rates was particularly evident following growth 
in 5mM glucose. In the PDK2 overexpressing cells, the rates of mitochondrial respiration were 
similar to the parental cells, apart for an increase in maximum respiration following growth in 
1mM glucose. Incubation with 25 mM glucose tended to reduce the respiratory activity, when 
compared to the 5 mM glucose condition, in the PDK overexpressing cells (Figure 3.8E-F). 
Hence, the effects of PDK1, PDK3 and PDK4 overexpression were less pronounced under this 
high glucose condition.  There was no significant difference in leak respiration among the 
groups, apart from a minor increase in PDK1 overexpressing cells.  
The maximum OCR in 231 WT cells were almost identical to their basal respiration rate, 
indicating that the WT cells might operate closer to their maximal capacity at basal levels. All 
OCR readings are normalized to cells’ protein content and presented after background was 
subtracted. Therefore, non-mitochondrial respiration is not shown in Figure 3.8D-F and the 






Figure 3.8 Analysis of mitochondrial respiration of 231 WT and 231 PDK1-4 cells. Oxygen 
consumption rate (OCR) was measured by Seahorse mitochondrial stress test in 1 mM, 5 mM, 
and 25 mM overnight glucose pretreatment with 30000 cells/well. The analysis was done in 
basal DMEM assay medium supplemented with 10 mM glucose, 2mM pyruvate, and 2 mM L-
glutamine. (A-C) Representative traces of OCR (pmol O2/min/µg protein) obtained after 
sequential addition of 3 µM oligomycin, 1 µM CCCP, 1 µM rotenone and 1 µM antimycin A. 
(D-F) Data extracted from A-C were analyzed to calculate basal respiration at normal 
condition; leak respiratory rate due to leakage of protons after oligomycin addition; maximum 
capacity (uncoupled respiration) after addition of CCCP; and CI-independent respiration after 
rotenone addition. Non-mitochondrial respiration or residual oxygen consumption is obtained 
after antimycin A addition. The results presented here are corrected for non-mitochondrial 
respiration and normalized protein content. The figures display representative data as mean ± 
SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 
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3.4.2 Analyzing the glycolytic function 
The glycolytic function of the PDK1-4 cells was assessed by measuring the extracellular 
acidification that is mainly generated by lactate secretion. The glycolysis stress test was 
performed, and interestingly 231 PDK1-4 cells also showed increased glycolytic rate compared 
to the 231 WT cells (Figure 3.9A-C). The PDK1-4 and WT cells had apparently same 
endogenous acidification rate (before adding glucose). After addition of glucose, the glycolysis 
rate was established and all the 231 PDK1-4 cells displayed higher basal ECAR following pre-
incubation in 1 mM glucose (Figure 3.9D). Subsequent addition of oligomycin blocks 
mitochondrial respiration, which causes a further increase in ECAR, indicative of the glycolytic 
capacity. The glycolytic capacity was also increased in the 231 PDK1-4 cells pre-incubated in 
1 mM glucose (Figure 3.9D).  The differences between 231 WT and 231 PDK1-4 cells 
regarding glycolytic rates were similar when comparing the higher glucose conditions (5 mM 
and 25 mM glucose) with the glucose restricted condition (1 mM glucose) (Figure 3.9E-F). 
Hence, these data did not convincingly suggest that differences in glucose supply causes 





Figure 3.9 Analysis of glycolytic function of 231 WT and 231 PDK1-4 cells. Extracellular 
acidification rate (ECAR) was measured by Seahorse glycolysis stress test in 1 mM, 5 mM, 
and 25 mM overnight glucose pretreatment with 30000 cells/well. The analysis was done in 
basal DMEM assay medium supplemented with 2 mM L-glutamine. (A-C) Representative 
traces of ECAR (mpH/min/µg protein), with sequential addition of 10 mM glucose, 3 µM 
oligomycin, and 100 mM 2-deoxyglucose (2-DG). (D-F) Data extracted from A-C were 
analyzed to calculate basal glycolysis and glycolytic capacity. Basal glycolysis- ECAR after 
addition of glucose; Glycolytic capacity- ECAR after addition of both glucose and oligomycin. 
The results are normalized to cell number and the figures display representative data as mean 





3.5 Characterizing the effect of PDK overexpression on substrate oxidation 
 
 
Figure 3.10 Effect of PDK overexpression in pyruvate and fatty acid oxidation was 
investigated in 231 WT and PDK1-4 overexpressing cells.  The cells were pre-incubated 
(overnight) with (A) 1 mM glucose, and (B) 25 mM glucose, and pyruvate oxidation was 
measured by trapping 14CO2 during 4h incubation in presence of [1-
14C]pyruvic acid (0.25 
µCi/ml, 200  µM total pyruvate concentration). The cells were pre-incubated (overnight) with 
(C) 1 mM glucose, and (D) 25 mM glucose, and fatty acid oxidation was measured by trapping 
14CO2-production during 4h incubation with [1-14C]palmitic acid (1 µCi/ml, 100 µM total 
palmitic acid concentration). The data presented are normalized to cell protein content (mg). 
The red arrows indicate the entry point of the 14C-labeled substrate into the metabolic pathway. 
The red and blue circles represent the released CO2 where the carbon is radiolabeled (red) or 
non-labeled (blue) respectively. The figures display representative data of three independent 
experiments with mean of replicates ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. 
 
3.5.1 Determining pyruvate and fatty acid oxidation rate and preferred substrate 
We wanted to investigate if increased PDK1-4 expression confers any changes in substrate 
oxidation rates of the cells, or causes a metabolic switch towards preferred substrate. To 
address such question, we used radiolabeled [1-14C]pyruvic acid and [1-14C]palmitic acid in 
assay medium together with respective non-radiolabeled substrates to determine pyruvate and 
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fatty acid oxidation rate by measuring 14CO2-production. Further, to evaluate effects related to 
glucose supply, the 231 WT cells and 231 PDK1-4 cells were pre-incubated overnight in 1 mM 
or 25 mM glucose. Generally, and especially regarding fatty acid oxidation, the oxidation rates 
were significantly higher in cultures pre-incubated with 1 mM glucose, compared to 25 mM 
glucose (Figure 3.10C-D).  
PDK-overexpression was expected to cause reduced PDH activity. Accordingly, we observed 
reduced pyruvate oxidation in 231 PDK1-4 cells compared to the WT parental cells, except for 
231 PDK1 cells pre-incubated with 1 mM glucose (Figure 3.10A-B). The relative effect of 
PDK1-4 expression in reduced pyruvate oxidation was some more significant following pre-
incubation in 25 mM compared to 1 mM glucose. 
On the other hand, 231 PDK1 and 231 PDK2 cells exhibited increased fatty acid oxidation 
following pre-incubation in 1 mM glucose, whereas 231 PDK3 and 231 PDK4 cells 
demonstrated increased fatty acid oxidation following pre-incubation in 25 mM glucose 
(Figure 3.10C-D). Apparently, the cells overexpressing PDK 1 or PDK2, similarly to the 231 
WT cells, were able to activate fatty acid oxidation to a higher extent than the 231 PDK3 and 
231 PDK4 cells, when they were placed in the low glucose condition compared to the high.  
In similar conditions, we also investigated glucose oxidation when [14C(U)]glucose was used 
as major substrate and no significant differences were observed in glucose oxidation between 
231 WT and 231 PDK1-4 cells (Supplementary Figure 8.3). We also collected media from the 
wells before adding radiolabeled substrates to determine the amount of glucose and lactate 
present in the media. Due to overnight incubation, there was no glucose left in the media in 1 
mM glucose treated cells. Supplementary Figure 8.4 shows glucose consumption and lactate 
production rate of 25 mM glucose treated cells. 
 
3.5.2 Characterizing pyruvate and fatty acid oxidation rates after specific pathway 
modulations  
We also wanted to investigate if uncoupling of mitochondrial inner membrane has any effect 
on pyruvate and fatty acid oxidation of the PDK-overexpressing cells. Besides, we treated the 
cells with inhibitors of pyruvate and fatty acid oxidation to test at what extent oxidation of 
these two substrates is inhibited. We used the same radiolabeled substrates in 14CO2-trapping 
method as described in section 3.5.1. This experiment was performed in association with the 
experiment presented in Figure 3.10 and the pyruvate and fatty acid oxidation data in Figure 
3.10 have been used as control data in Figure 3.11. The use of 1 µM CCCP did not seem to 
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have very much effect on pyruvate oxidation (Figure 3.11A-B). Conversely, CCCP caused a 
drastic increase in palmitic acid oxidation in both glucose conditions (1 mM and 25 mM), again 
indicating fatty acids as preferred substrate for the 231 PDK1-4 cells (Figure 3.11C-D) 
Upon treatment with MPC inhibitor UK-5099 and CPT-1 inhibitor etomoxir, pyruvate and fatty 
acid oxidation was almost blocked. The residual portions of the pyruvate and fatty acid 
oxidation after UK-5099 and etomoxir treatment indicates non-mitochondrial substrate 
oxidation. 
Furthermore, the cell associated radioactivity was calculated after the trapping procedure upon 
lysing of the cells with 0.1 M NaOH. No significant differences were observed associated with 
[1-14C]pyruvic acid activity but a slight increase in [1-14C]palmitic acid activity was visible in 
compared to WT. Supplementary Figure 8.5 shows the concentration-dependent changes in the 




Figure 3.11 Effect of mitochondrial uncoupler and pyruvate and fatty acid oxidation 
inhibitors on 231 PDK1-4 cells. Pyruvate oxidation was measured from [1-14C]pyruvic acid 
(0.25 µCi/ml, 200  µM) after being treated with an uncoupling agent CCCP (1 µM) , and MPC 
blocker, UK-5099 (10 µM) in (A) 1 mM and (B) 25 mM pre-treated glucose condition . Fatty 
acid oxidation was measured with [1-14C]palmitic acid (1 µCi/ml, 100 µM) after treated with 
CCCP (3µM) and mitochondrial β-oxidation inhibitor, etomoxir (40 µM). Data presented as 
mean of replicates ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. MPC- 




3.5.3 Effect of DCA-mediated PDK inhibition on pyruvate and fatty acid oxidation 
Further we wanted to investigate if DCA-mediated inhibition of PDKs can reactivate PDH 
function, thereby increasing pyruvate oxidation. We also wanted to look at associated effects 
of DCA on palmitic acid oxidation. To study this, we performed 14CO2-trapping analysis with 
[1-14C]pyruvic acid (0.25 µCi/ml, 200 µM) and [1-14C]palmitic acid (1 µCi/ml, 100 µM) as 
described above sections, following incubation under normal culturing conditions (25 mM 
glucose). The experiment was performed with 20 µM, 30 µM, 40 µM, and 50 µM DCA in 
order to find out the dose-dependent effects of DCA on PDH activity.  
Figure 3.12 represents the rate of substrate oxidation in presence of different DCA 
concentrations. Following 4 h of trapping, no significant differences were observed in pyruvate 
oxidation between the untreated and DCA-treated groups (Figure 3.12A-E). Though 231 PDK3 
cells tended to have slightly increased pyruvate oxidation in presence of 30, 40 and 50 µM 
DCA, this was not statistically significant. Hence, these data did not support that DCA causes 
increase pyruvate oxidation upon regaining of PDH activity. Interestingly, significant 
differences were observed in fatty acid oxidation. Higher DCA concentrations (40, 50 µM) 
almost blocked palmitic acid oxidation (Figure 3.12 F-J) in each of the cell types. The lowest 
DCA concentration (20 µM) inhibited fatty acid oxidation in 231 WT and 231 PDK1 cells, but 
not the others.  The results from this experiment need further validation since it was not possible 




Figure 3.12 Effect of DCA treatment on pyruvate and fatty acid oxidation. 231 WT and 
PDK1-4 cells were seeded as 45000 cells/well in 96-well CellBind® microplates and incubated 
overnight in 25 mM glucose condition. DCA titration with 20 µM, 30 µM, 40 µM, and 50 µM 
concentrations was done prior to 4 h trapping in presence of radiolabeled pyruvic acid (0.25 
µCi/ml, 200 µM) and palmitic acid (1 µCi/ml, 100 µM). (A-E) Pyruvate oxidation rate in cell 
affected by varying DCA concentrations compared to untreated (F-J) Fatty acid oxidation rate 
in each cell affected by varying DCA concentrations compared to untreated. Data presented as 




In this study, we investigated the effect of PDK overexpression in cultured cells under different 
conditions of energy stress. We explored changes in cellular features and metabolic functions 
due to PDK overexpression, and found that the given metabolic defects triggered potential 
rescue mechanisms involving metabolic adaptations to the conditional changes. 
 Since energy is vital for survival, cells are provided with precise mechanisms to maintain 
proper energy balance and to elicit stress protection responses when needed [51]. Cells have 
metabolic flexibility that enables them to switch between different pathways or substrates 
depending on the cellular energy demand or the availability of nutrients and oxygen. Metabolic 
defects may compromise such ability when the limit exceeded resulting in cellular energy 
failure with possible consequences of mild cellular stress to cell death [12]. To counteract 
energy depleted cellular state, cells must activate adaptive mechanisms which theoretically can 
be referred as metabolic rewiring. Some of the effects of metabolic stress or defects can be 
mimicked in vitro in cultured cell models, and thus can help to characterize mechanisms of 
metabolic adaptation triggered by those metabolic defects and energy stress.  
In this thesis, we interfered with the PDH activity by inducing upregulation of its negative 
regulator, PDK and then investigated how the cell metabolism and mitochondrial functions are 
affected in the manipulated cells due to PDK overexpression. The cell model used for this 
manipulation was the immortalized cell line MDA-MB-231 that represents a highly malignant 
and poorly differentiated human breast adenocarcinoma line [115]. The use of immortalized 
cell lines offers enormous possibilities of easy handling and limitless replicative potential. 
Since they are immortalized and can be grown continuously in culture, they produce 
comparably a more homogeneous population of cells. They provide advantage experimental 
replications, and often can tolerate robust treatment conditions which make them ideal to be 
used as stable cell model. The use of immortal cell lines is not always optimal. Since they are 
not normal human cells anymore and many of them have been passaged for decades, they do 
not resemble original cell state since they are prone to genotypic and phenotypic changes  [116-
118] . 
Besides genetic manipulation via PDK overexpression, we created environmental stress by 
variable glucose conditions, low oxygen, treatment with different metabolic inhibitors and 
modulators and mitochondrial uncouplers. We then employed different strategies to investigate 
changes in cell morphology, growth, substrate use and metabolic functions which are discussed 
below in line with the results obtained. 
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4.1 Stable transduction leads to significant upregulation of PDK  
All four isoforms of PDK were introduced in MDA-MB-231 cell by retroviral transduction and 
this study demonstrates characterization of these four PDK1-4 overexpressing cells. This 
overexpression strategy facilitated comparison of the metabolic status and mitochondrial 
function of 231 PDK1-4 cells with their WT parental cell. At first, induced expression of all 
four PDKs was confirmed by qPCR and western blot analysis. The PDK1, PDK2, PDK3 and 
PDK3 probes used were sensitive enough to detect high mRNA expression of respective PDK 
isoforms in the transduced cells whereas the non-overexpressed PDKs had significantly lower 
level, comparable to the WT parental mRNA sample (Figure 3.1). The presence of other 
endogenous PDKs in each of the PDK overexpressing cells were also found to be low. This 
might not due to the sensitivity of the probes, rather might be the cell and tissue -specific 
expression manner of the PDK isoforms [54]. This has been reported by many that PDK2 and 
PDK4 are predominantly expressed in metabolically active tissues like liver, skeletal muscle, 
heart, and kidney during starvation whereas PDK1 exclusively expressed in heart and PDK3 
in brain and testes [72, 119]. Since we used MDA-MB-231 cell line for our study, these cells 
predominantly express PDK2 and low levels of the other PDK isoforms naturally [120]. 
However, qPCR analysis confirmed significant upregulation of PDK1-4 upon overexpression, 
based on their high fold change, though the level of expression was very different among the 
PDKs, ranging between 60-2000-fold. This might due to the variation in copy number of the 
PDK mRNAs since a high copy number positively correlates with high expression, which in 
turn can affect the overall expression of the proteins [121].  
A second qPCR quantification also confirmed the presence of inserted constructs (Figure 3.1B) 
again after a selection process, but the fold changes were reduced to 30- to 350-fold, 
particularly for the PDK1 and PDK4. One possible reason behind this may be that the part of 
the vector genes might be lost from the pool because of continuous passaging or the cycles of 
freezing and thawing somehow affected the gene expression. Another anticipation is that we 
did not make the cell population from a single clone, rather with all surviving clones after the 
selection process. Some of them might express the gene required to survive selection, but not 
the gene we want to over-express. They might grow together with overexpressing cells and 
eventually result in loss of expression of the target gene within the population (selection 
processes) [122]. Even though having lower expression than the first measurement, PDK4 was 
the highest expressed isoform among the other three. The high expression of PDK4 suggests 
that it may contribute to the regulation of long-term adaptive response of PDH activity [119]. 
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We quantified qPCR data by normalizing to the endogenous reference control, 18S rRNA. 
Kuchipudi et al. reported that 18S rRNA is the best reference gene upon testing and comparing 
a set of housekeeping genes [123]. It has a low turnover rate, less prone to changes due to 
physiological perturbation, and has invariant expression in different organisms, tissues, 
treatments and developmental stages. One technical limitation of using 18S rRNA is that it 
lacks poly-A tail, therefore random primers must be used rather than oligo-(DT). Another 
problem is that 18S rRNA is more abundant than any other typical mRNA transcripts and thus 
requires dilution to reach the threshold value within the dynamic range of qPCR reaction [123, 
124].  
Western blot data in Figure 3.2 that shows the protein level expression of PDK1-4 isoforms are 
also in agreement with the qPCR data. The anti-PDK (1-4) antibodies detected the expression 
of target PDKs (1-4) in the respective overexpressed cell with high intensity bands. We had all 
five protein samples (including the 231WT) in a single blot and the expression of other PDK 
proteins in each overexpressed cell was detected as low. The same was observed in the WT 
protein sample, indicating downregulation of all four PDK proteins due to poor intensity 
signals. We used separate blots for each anti-PDK antibody because the four PDK1-4 proteins 
have very close molecular weight (MW, 46-49 KDa) and the bands are detected at 
approximately 46 KDa, otherwise the bands might be produced in overlapped with each other 
making them difficult to differentiate. The same problem happened with the use of α-tubulin 
as a loading control, α-tubulin has a MW of approximately 50 KDa which is close to the PDKs’ 
MW. Thus, the bands detected via anti- α-tubulin were in overlapping position with the PDK 
bands that made the quantification procedure difficult. As a result, we continued with the anti-
GAPDH antibody which has a MW of 35.8 KDa, and the bands produced were clear enough 
to perform a proper quantification.  Though some researchers recommend not to use GAPDH 
since it is a metabolic enzyme and can bind to other proteins and the expression is sometimes 
not stable [125], it was found to be quite good but for our purpose. The molecular weight for 
the bands of interest was evaluated by comparison to the size of the standard protein bands and 
was found as reproducible.  
4.2 PDK overexpression is associated with increased proliferation in 231 PDK1-4 cells 
and is affected by glucose limitation  
Proliferation study found that the PDK1,3 and 4 overexpressing cells tended to grow faster than 
the parental WT cells, whereas the 231 PDK2 had slightly reduced proliferation. This was 
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confirmed by measurement of impedance analysis in the xCELLigence instrument. Unlike 
from the conventional end-point based proliferation assays, the xCELLigence system provides 
the advantage of non-invasive monitoring of cell growth including cell adhesion, spreading and 
proliferation [126]. Since the system detects impedance based on cell attachment, the data we 
have shown in Figure 3.3 was normalized to first 5 hours after the experiment started (i.e 2h 
after cell seeding) so that the cells were properly attached to the bottom of the wells. The cell 
number we used (4000 cells/well) was previously been optimized for similar types of cells in 
our lab, but the growth curves of 231 PDK1-4 did not seem to reach to their maximum cell 
index, indicating that the cell number was not optimal for these cells. Since cell number 
correlates very well with impedance-based monitoring of proliferation, we tried measuring 
proliferation with higher cell densities but the results were not satisfactory. One possible reason 
behind this was explained by Man I et al, who found that the quality of the assay is limited by 
overgrowth of the cells in the wells at very high cell densities,  as well as lack of nutrients in 
the culture media [126]. Therefore, we continued with the 4000 cells/well density. We 
calculated proliferation rate of the 231 PDK1-4 cells every 24 hours and obtained the similar 
trend in each time points (Figure 3.3B); 231 PDK1, PDK3, and PDK4 had increased 
proliferation while PDK2 had reduced proliferation compared to the WT. Our findings suggest 
that the overexpression caused metabolic adaptation and a subsequent change in their 
proliferation rate compared to their parental line.  
Media was collected form the wells at 24h, 48h, 72h, and 96h, and the concentrations of glucose 
and lactate present in media was measured (Figure 3.4). This was done mainly to investigate 
how much glucose was utilized by the cells and how much lactate was produced as a 
consequence. Interestingly, the glucose level was not that much reduced throughout the 96 
hours of growth, and remained around 18-20 mmol/L. This was surprising, since the cells 
produced up to 5 mmol/L lactate, which is anticipated to originate via glycolytic breakdown of 
glucose. One possible explanation is that the cells might use another energy source present in 
the media, for instance glutamine, thus maintaining the glucose concentration at a high level. 
Another possibility is, we used FBS in media which might contribute to dilution of the glucose 
concentration in the media. This is the probable reason that we observed 18-20 mM glucose in 
blank medium instead of 25 mM. 
 
We also characterized effect of glucose deprivation on 231 PDK1-4 proliferation by incuCyte 
image sequence analysis and resazurin conversion. Several studies have shown that the level 
of glucose has important effect on cellular responses, and the range of its effect varies from 
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cell type to cell type [62, 127, 128]. Moreover, the required concentration of glucose in 
commercial cell culture media often exceeds the glucose level of normal physiological 
condition (during fasting ~4 mM, after meal ~7.8 mM) [129, 130]. We hypothesized that 
regulation of the PDH complex through altered expression of PDKs may lead to metabolic 
adaptations that changes the response to glucose variations, with regards to cell growth. 
Therefore, we treated the 231 PDK1-4 cells with three different concentrations of glucose, 
limited supply (1 mM), average supply (5 mM), and high glucose state (25 mM). The growth 
of the cells was then monitored using the incuCyte imaging instrument, under the same 
incubation condition as the cells were usually maintained (21% O2, 5% CO2, 37
0C). The growth 
of the 231 PDK1-4 cells were significantly affected by the glucose limited condition (1 mM) 
compared to the two conditions with higher glucose concentrations, as presented by the growth 
curves in  
Figure 3.5. The cultures provided 1 mM glucose grew for approximately 40 h before the cell 
density reached a plateau and later started to decline, probably due to glucose deprivation. 
Interestingly, the 231 PDK1 and 231 PDK2 cells appeared to reach glucose deprivation before 
the three other cell types, however, the growth curves of all the 231 PDK1-4 cultures tended to 
be below the 231 WT cells in the critical phase when glucose became limiting. This may 
indicate that the PDK overexpressing cells are more dependent on glucose, but this will have 
to be confirmed in repeated studies. Overexpression of PDK1-4 did not change the growth in 
5 mM glucose, compared to the control, but 231 PDK3 cells displayed slightly increased 
growth in 25 mM glucose.   
 
To investigate effects on cell viability, the cells were cultured for 72 h under the same glucose 
conditions as the incuCyte experiment, before we carried out the resazurin conversion assay 
(Figure 3.6). The data did not suggest the PDK1-4 overexpressing cells have reduced tolerance 
for low glucose availability (1 mM glucose), compared to the parental cells. However, this 
represents an endpoint measurement, and comparing with the incuCyte analysis, it may seem 
that this timepoint (72 h) was too late to cover the most critical phase.  In 5 mM and 25 mM 
glucose, we generally observed increased viability in PDK overexpressing cultures compared 
to WT cultures. This is relatively consistent with the effects we observed with the other 
methods of cell proliferation. It is important to be aware that the methods of cell viability and 
growth employed in this project (xCELLigence, incuCyte, resazurin) assess different cellular 
features, and therefore may show some variability. For example, 231 PDK1 was found to have 
the highest proliferation rate, and the 231 PDK2 had the lowest, in xCELLigence analysis, 
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whereas the same was not observed in incuCyte and resazurin assay. Such differences may be 
explained by variations between the detected features (e.g. metabolism versus cell number), as 
well as inter-experimental variations that is always an issue in cell culture experiments. Further, 
cellular resazurin conversion depends on metabolic activity, and may be affected by changes 
in mitochondrial metabolism which we found changed in the 231 PDK1-4 cells. Besides, the 
concentration and incubation time of resazurin is also important due to its ability to induce 
stress mechanisms that lead to reduced proliferation and mitochondrial dysfunction in cultured 
cells. According to Erikstein et al resazurin exposure was used as a model in investigating 
cellular stress mechanisms in two leukemia cell lines, HL-60 and Jurkat in one of their studies. 
They showed that resazurin reduced cell proliferation which ultimately led to autophagy and 
cell death through the generation of ROS, and concluded resazurin as a toxic mediator of 
cultured cells [131]. So, care should be taken while using this reagent since it affects vital 
mechanisms of cellular homeostasis. Therefore, we used 1x diluted concentration of 20x 
2.5mg/ml resazurin stock and exposed the cells only for 3h to resazurin. 
4.3 PDK overexpression is associated with increased mitochondrial respiration and 
glycolysis 
In order to investigate if metabolic adaptation occurred in 231 PDK1-4 cells, we measured 
mitochondrial respiration and glycolysis by the seahorse analyzer. The OCR measurement by 
the mitochondrial stress test indicates how the mitochondria operate when exposed to their 
weaknesses and also an indicator of overall cellular health [87, 132]. Similarly, measurement 
of ECAR is the determinant of glycolytic capacity [110].  
Analysis of OCR revealed that 231 PDK1-4 cells had higher rates of mitochondrial respiration 
compared to the WT parental cells; however, this difference was some less pronounced after 
culturing in 1 mM glucose, compared to 5 mM glucose.  In particular, the 231 PDK1, PDK3, 
and PDK4 cells demonstrated markedly increased basal mitochondrial respiration, ATP-linked 
respiration as well as maximum capacity in 5 mM glucose condition (Figure 3.8 C-D). 
Interestingly, the rate of increased mitochondrial respiration in 231 PDK1, PDK3, and PDK4 
was somewhat less evident in 25 mM glucose in compared to 5 mM glucose. These glucose-
dependent effects on mitochondrial respiration was found to be different in PDK2 
overexpressing cell, almost similar to the rate of mitochondrial respiration in 231 WT cell, 
particularly in 5 mM and 25 mM glucose. Apparently, very low proton leak was observed in 
each condition (See Figure 3.8D-F) indicating that the mitochondrial integrity is intact, and the 
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mitochondrial membrane potential remained unchanged in these cells. So, based on the data 
observed in this study, we interpret that PDK overexpression causes an increased electron flow 
throughout the respiratory chain in 231 PDK1, PDK3, and PDK4 cells and is coupled to 
elevated oxidative phosphorylation. However, the optimal CCCP concentration we chose for 
this study was 1 µM, even though 1.5 µM and 2 µM did also produce quite good respiration 
profile. CCCP is a strong uncoupler and too high concentration of uncouplers can inhibit 
mitochondrial function or cause mitochondrial dysfunction [133]. 
Similarly, we observed increased rates of glycolysis in the 231 PDK1-4 cells, compared to 231 
WT cells. The basal glycolysis as well as the glycolytic capacity of the 231 PDK1-4 were 
significantly higher than WT cells in all glucose conditions (Figure 3.9). When cells experience 
loss of ATP production in mitochondria due to inhibition of oxidative phosphorylation, either 
blockage by oligomycin or by low-oxygen tension, they divert cellular metabolism towards 
glycolysis to make more ATP to maintain cellular energy homeostasis [134]. Similarly, for 231 
PDK1-4 cells, we assessed their maximum capacity upon inhibition of mitochondrial 
respiration by oligomycin. Nevertheless, the ECAR profile of 231 PDK1-4 cells demonstrates 
very high glycolysis rate in these cells than the parental cells but that does not necessarily mean 
that the cells are highly glycolytic, since the effects on mitochondrial respiration and glycolysis 
seemed relatively balanced. Furthermore, the ECAR data suggests that difference in glucose 
supply does not cause any metabolic adaptation in the glycolytic machinery of the PDK-
overexpressing cells. However, if the conditions changed, for example nutrient restriction, use 
of other substrates except glucose (e.g galactose), and treatment with different modulators 
might produce different OCR and ECAR profile in these cells. Again, the measurement of 
complex-I independent OCR by rotenone, non-mitochondrial OCR by antimycin-A and non-
glycolytic ECAR by glucose analog 2-DG provided true baseline measurement of OCR and 
ECAR respectively, at the same time indicated the high sensitivity of the seahorse technique 
[109].  
4.4 PDK overexpression in 231 PDK1-4 cells leads to increased fatty acid oxidation 
Cells tend to rewire their metabolic pathways in order to meet their metabolic energy demands 
and homeostasis. We hypothesize that in contexts of limited glucose supply, there might be a 
metabolic switch towards increased fatty acid oxidation in the 231 PDK1-4 cells. In this 
project, we investigated pyruvate and fatty acid oxidation capacity of 231 PDK1-4 cells and 
particularly focused, and searched for any shift in substrate preference under high and limited 
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glucose supplied conditions. During in vitro studies with cultured cells, mitochondrial pyruvate 
and fatty acid oxidation can be assessed by using radiolabeled pyruvate and fatty acid substrates 
as described by Wensaas et al [112]. Therefore, we used [1-14C]pyruvic acid (0.25 µCi/ml) and 
[1-14C]palmitic acid (1 µCi/ml) followed by trapping and quantifying the 14CO2 produced from 
the 231 PDK1-4 cells. The advantage of this method is that it uses 96-well tissue culture plates 
with an inverted filter plate on top to capture the 14CO2 produced by the cells instead of using 
conventional tissue culture flasks to trap the 14CO2 from isolated organelles, enzymes or intact 
cells.  
We observed that upregulated PDK3 and PDK4 expression tended to cause increased basal 
mitochondrial fatty acid oxidation rate particularly in 25 mM glucose whereas PDK1 and 
PDK2 tended to cause increased fatty acid oxidation in 1 mM glucose, compared to their WT 
parental cells. Conversely, PDK-overexpression was associated with reduced pyruvate 
oxidation rate in these cells (Figure 3.10). Since PDK1-4 are the four regulatory kinases of 
PDH that phosphorylate and inhibit PDH [72], the PDH enzyme might be inactive or less active 
due to PDK overexpression in the 231 PDK1-4 cells.  Therefore, the cells were found to 
mediate a metabolic switch from pyruvate to fatty acid oxidation. Interestingly, the PDK-
overexpressing cells were able to activate fatty acid oxidation to a higher extent in glucose 
limited condition (1 mM) than in the 25 mM glucose, supporting the fact that the adaptation to 
fatty acid metabolism is stimulated by glucose deprived or glucose limiting conditions.  
This kind of metabolic shift towards increased oxidation of fatty acid instead of glucose 
substrate indicates a causative relationship between PDK overexpression and fatty acid 
oxidation [135]. Several studies have shown rewiring of metabolic pathways in contexts of 
substrate utilization in relation to PDK4. Pettersen et al (unpublished work) showed that PDK4 
was simultaneously upregulated with fatty acid oxidation related genes in rat liver and heart. 
They also reported increased fatty acid oxidation in cultured MDA-MB-231 and Hela cells 
with overexpression of PDK4, concluding that PDK4 can be used as a surrogate marker for 
stimulated fatty acid oxidation [135]. Chambers et al showed that cardiac specific 
overexpression of PDK4 in transgenic (myosin heavy chain (MHC)-PDK4) mice exhibits 
insulin-resistant substrate oxidation profile, characterized by low glucose but high fatty acid 






4.5 Characterizing the effects associated with metabolic inhibitors and modulators in 
231 PDK1-4 cells 
We evaluated the effects of different modulators and inhibitors on 231 PDK1-4 cells in relation 
to cell proliferation, substrate utilization, and cellular and mitochondrial functions. The effects 
of respiratory chain and glycolysis modulators have been discussed in the seahorse section. 
However, we examined some other conditions to further investigate the effect of PDK 
overexpression in substrate oxidation in presence of inhibitors of glucose and fatty acid 
metabolism. Since, CPT1 controls the mitochondrial import of fatty acids for β-oxidation as 
well as MPC controls the pyruvate import [137], we incubated the 231 PDK1-4 cells with the 
inhibitors of CPT1, etomoxir and MPC inhibitor, UK-5099. Both of them markedly inhibited 
pyruvate and fatty acid oxidation (Figure 3.11), indicating that both pyruvate and fatty acids 
need specific transporters for their import to mitochondria. This is also an indicator that 
mitochondria have vital role in substrate oxidation as well as maintain a balanced metabolic 
state in the cell. In contrast with these inhibitory effects, incubation with the uncoupling agent 
CCCP resulted in a small increase in the rate of fatty acid conversion into 14CO2, but the effect 
was not visible in pyruvate oxidation. 
 
We also looked at how DCA-mediated inhibition of PDK influence 231 PDK1-4 cells’ 
proliferation and substrate oxidation rate. Since the cells were found to be dependent on 
glucose, we used 25 mM glucose condition to execute the effect of DCA. Initially we tried with 
lower concentration of DCA (10 mM, 20 mM for instance), but no effect was observed, and 
finally we were able to see a significant effect on cell proliferation at 50 mM DCA 
concentration. This concentration was found to be effective in some other cells as well in our 
laboratory. As suggested by Bell et al and Woo et al, PDK2 is most susceptible to DCA due to 
its ubiquitous expression pattern whereas PDK3 is least sensitive [66, 76], we found such effect 
in very small extent in our cells. Rather, DCA inhibited proliferation in each of the cells (Figure 
3.7). This finding can provide insights on the usefulness of DCA in targeting cancer cells with 
increased PDK expression. Michelakis's group in 2007 reported that DCA is uniquely toxic to 
human cancer cells and particularly inhibited the proliferation of human non-small cell lung 
cancer (A549) tumor xenografts in rats [138]. Other researchers also support that DCA therapy 
could slow down the formation of cancer, decrease the tumor volume, reduce the rate of 
proliferation, and could trigger cancerous cell apoptosis. DCA was also found to downregulate 
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expression of few genes required for cancer survival, for example, suppression of HIF-α 
expression in cancer cells with high PDK4 expression [139].  
We also aimed that inhibition of PDK by DCA might increase mitochondrial pyruvate 
oxidation by activating the PDH complex. It is also an established therapeutic strategy for 
reversing the Warburg effect in cancer cells that eventually increase the OXPHOS [139]. For 
our 231 PDK1-4 cells, instead of increasing, DCA showed a negative effect on the conversion 
of [1-14C]pyruvate into 14CO2, though a minimal effect was visible in 231 PDK3 cells. One 
possible reason is, since PDK1-4 are highly expressed in the 231 PDK1-3 cells, higher 
concentration of DCA even more than 50 mM might be needed to fully inhibit the PDKs.  Fatty 
acid oxidation was also drastically reduced upon treatment with DCA, indicating that PDK1-4 
were actually inhibited (Figure 3.12). Both these findings gave rise to contradictory 
interpretations. Therefore, a measurement of end-point lactate level can be an indicator of PDK 
inhibition. A decreased level of lactate in the media is the immediate result of PDK inhibition 
in cells [140]. However, we do not rely very much on this finding since we need to optimize 
the DCA concentration further and also need to repeat this experiment few times.  
 
5 Concluding remarks 
In this study, our main aim was to investigate mechanisms of metabolic adaptation upon genetic 
manipulation in cultured cells, and how these are influenced by energy stress and mitochondrial 
modulation. We introduced PDK1-4 overexpression in MDA-MB-231 cells and gene 
expression study confirmed that the PDK1-4 are highly expressed in the respective cells. 
Subsequently, metabolism in cells overexpressing PDK1, PDK3, and PDK4 was found to be 
characterized by increased rates fatty acid oxidation, glycolysis and mitochondrial respiration, 
and generally accompanied by increased proliferation. Interestingly, high PDK1-4 expression 
appeared to reduce the capacity of metabolic adaptation in response to reduced glucose supply, 
possibly since the rates mitochondrial oxidation and respiration were already high under well-
supplied glucose conditions. Taken together, and supported by the proliferation studies, the 
findings further support that the PDK overexpressing cells are more dependent on glucose for 
optimal growth.  
The increased metabolic rates are consistent with increased growth. Modulation of 
mitochondrial ETC and glycolysis confirmed that the integrity of glycolysis and mitochondrial 
respiration was intact. One remarkable finding of our study was that PDK overexpression 
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tended to cause a metabolic shift from pyruvate to fatty acid oxidation, indicating a metabolic 
adaptation towards increased rates of mitochondrial fatty acid oxidation. Inhibitors of pyruvate 
and fatty acid transporters were used to confirm the specificity of the measurements. The PDK 
inhibitor DCA was found to be a highly capable inhibitor of proliferation and fatty acid 
oxidation in this model. 
The data generated from this study put insights on how cells rewire their metabolism upon 
genetic modulation and conditional energy demands and also some implications related to PDH 
impairment in cell. 
 
6 Future perspectives 
In our study, we have investigated the effect of PDK overexpression and characterized the 
associated mechanisms of metabolic adaptation in terms of proliferation, viability, glucose 
dependency, mitochondrial respiration, glycolytic capacity, and substrate oxidation rate in 
cultured cells. Though most of the other studies that have been done so far related to PDK 
overexpression are based on PDK4 expression, we have been able to characterize increased 
expression of all four PDK4 isoforms in our cell model. Some of the works need to be repeated 
for more reliable data. For example, we tried to regain PDH activity and subsequent pyruvate 
oxidation by inhibiting PDK with DCA. This could be a good approach to confirm the effects 
of PDK overexpression. However, some further optimization of experimental methods and 
DCA concentration will be necessary. Treatment with other inhibitors, such as PDK subtype 
specific inhibitors, may also be included to further pursue the experimental findings in this 
thesis. We found potential effect on glucose dependency of the PDK overexpressing cells. To 
further investigate this effect, it could be a good idea to study cellular proliferation in presence 
of other carbohydrate sources, such as galactose which is known to require mitochondrial 
metabolism to obtain a net yield of ATP. Due to time limitation, we were not able to investigate 
the effect of hypoxia in cell growth, which we intend to do in future; however, we managed to 
see the effect under normoxic condition to some extent.  
Our next plan is to carry out gene expression study on OXPHOS proteins and fatty acid 
oxidation related genes in these cells as well as to look at nutrient- and energy-sensitive factors 
such as expression of AMPK, the family of peroxisome proliferator-activated receptor 
transcription factors (PPARs), and the activation of Akt/mTOR. Besides, we will be looking at 
mitochondrial respiration and substrate oxidation rate after treatment with different modulators 
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such as pharmacological activator of AMPK (5-aminoimidazole-4-carboxamide 
ribonucleotide, AICAR), PPARα-agonists, such as WY-14,643, modified fatty acids (e.g 
tetradecylthioacetic acid, TTA) and other uncouplers such as 2,4-Dinitrophenol (DNP). 
Another future direction might include investigating the effect of metabolic modulation on 
ROS production for instance, by flow cytometry.  
We also look forward to investigate the involvement of PDK overexpression in any particular 
disease and if it contributes to therapy resistance. Furthermore, data generated from in vitro 
studies often require validation via in vivo studies. Since PDKs are extremely tissue specific, 
in vivo studies will provide tissue specific expression profile of PDK 1-4 isoforms as well as 
substrate oxidation rate in different tissues after being treated with modified high-fat or 
glucose-rich diet. We also have other cell lines with PDK overexpression in our lab (e.g Hela, 
C2C12, Huh7), so comparing the effects of PDK overexpression in cellular and metabolic 
changes between cell lines will be another possible approach for rewiring of metabolism. In a 
manuscript currently under evaluation for publication in a scientific journal, we characterized 
PDK4 mRNA expression as a sensitive surrogate marker of fatty acid oxidation. Therefore, we 
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8.1 Effect of low oxygen condition in the viability of PDK-overexpressing cells 
 
Figure 8.1 Comparison of cell viability in PDK-overexpressing cells under normal and 
physiological oxygen condition. The measurements were done with 3000 cells/well after 72 h 
incubation, followed by 3h resazurin conversion assay. Resazurin fluorescence indicating differences 
in viability between normal (21%) and low oxygen (5%) condition in (A-B) 1 mM glucose, (C-D) 5 
mM glucose, and (E-F) 25 mM glucose. The graphs represent mean of three technical replicates ± SD. 




8.2 Determination of optimal CCCP concentration for assessing maximum 
mitochondrial respiration  
 
Figure 8.2 Mitochondrial stress test to determine optimal CCCP concentration. Oxygen 
consumption rate (OCR) was measured in basal DMEM assay medium supplemented with 10 
mM glucose, 2mM pyruvate, and 2 mM L-glutamine with 30000 cells/well.  Representative 
traces of OCR (pmol O2/min/µg protein) obtained after sequential addition of 3 µM 
oligomycin, CCCP (0.25 µM, 0.5 µM, 1 µM, 1.5 µM, and 2 µM), 1 µM rotenone and 1 µM 
antimycin A in (A-B) 231 WT cells and (C-D) 231 PDK4 cells after overnight pretreatments 
with 1 mM and 25 mM glucose respectively. (E-H) Data extracted from A-B and C-D were 
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analyzed to calculate basal respiration, leak respiratory rate due to leakage of protons after 
oligomycin addition; maximum capacity (uncoupled respiration) after addition of CCCP, and 
CI-independent respiration after rotenone addition. The results presented here are corrected for 
non-mitochondrial respiration and normalized protein content. The figures display 
representative data as mean ± SEM.  
 
 




Figure 8.3 Effect of PDK overexpression in the glucose oxidation  of 231 WT and 231 
Glucose oxidation was measured by trapping 14CO2-production during 4h incubation with [U-
14C]Glucose (4 µCi/ml, 5  mM total glucose concentration) after overnight pre-treatment with 
(A)1 mM glucose, and (B) 25 mM glucose  (C) After overnight pre-treatment with 1 mM 
glucose, and (D) 25 mM glucose. The data presented here are normalized to cell protein content 
(mg). The figures display representative data of three independent experiments with mean of 




















8.4 Measurement of media glucose and lactate  
 
Figure 8.4 Measurement of glucose and lactate present in the cell culture media after 
overnight pretreatment in 25 mM glucose. The measurements were done before substrate 
oxidation experiment by 14CO2-trapping. Estimated glucose concentration present in the media 
was ranging between 18-20 mmol/L in 231 WT and 231PDK1-4 cells. Estimation of 
extracellular lactate concentration was higher in 231 PDK1-4 than 231 WT culture media, 




























8.5 Determination of cell-associated radioactivity in 231 PDK1-4 cells 
 
Figure 8.5 Cell associated radioactivity measured from the cell lysates of 231 WT and 231 
PDK1-4 cells. (A-B) Accumulation of [1-14C]pyruvic acid  in presence of 1 µM CCCP and 10 
µM UK-5099 in 1 mM and 25 mM pre-treated glucose condition respectively. (C-D) 
Accumulation of [1-14C]palmitic acid  after treated with 3µM CCCP and 40 µM etomoxir in 1 
mM and 25 mM pre-treated glucose condition respectively. Measurements were after 2 





Table 8.1 The qPCR ddCT values of the all PDK expression in each of the PDK-
overexpressing cell 
Cell types PDK1+18S PDK2+18S PDK3 +18S PDK4+18S 
231 WT 1.00  1.00  1.00  1.00 
231 PDK1 35.80  0.89  0.78  1.28 
231 PDK2 0.72  82.74  0.33  0.80 
231 PDK3 0.68  1.16  145.74  0.98 
231 PDK4 0.25  0.67  0.36  344.21 
 
